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The involvement of prostaglandins in the processes of
parturition and implantation in the rat has been studied.
The release of prostaglandins and thromboxane from the term
(day 22) pregnant rat uterus in vitro has been measured using
radio-immuno-assay, gas chromatography combined with mass spectro¬
metry and a platelet aggregation method. Prostaglandin l£ and
thromboxane A2 (measured as their metabolites 6-oxo-prostaglandin
and thromboxane B2 respectively), were found to be released in
large amounts, with prostaglandin F2 and prostaglandin E2 being
released in smaller amounts. The compound released in by far the
largest amounts was found to be prostaglandin D2. Possible roles
for these prostaglandins at parturition in the rat, are discussed.
The treatment of the day 22 pregnant rat uterus in vitro,
with the prostaglandin I0 synthesis inhibitors,15-hydroperoxy
arachidonic acid and tranylcypromine has been investigated. Both
compounds caused a spasm of the tissue when added to the bathing
fluid. 15-hydroperoxy arachidonic acid caused a dose-dependent
increase in the release of prostaglandins, while tranylcypromine
caused a fall in the release of prostaglandin E2, but did not affect
the release of other prostaglandins. Possible mechanisms for the
effect of 15-hydroperoxy arachidonic acid on prostaglandin release
from the term pregnant rat uterus, are discussed.
The production of prostaglandins by the early pseudopregnant
and early pregnant rat uterus in vitro has been studied. 6-oxo-
prostaglandin F-j^ was the major product in both early pseudo-
pregnancy and early pregnancy. Production of prostaglandin E2,
prostaglandin ^2cx. an<^ 6-oxo-prostaglandin F-j ^ showed a peak on
day 5 of pseudopregnancy. Prostaglandin E2 and 6-oxo-prostaglandin
Fj^ only showed a peak on day 5 of pregnancy. Total prostaglandin
production was higher during pregnancy than during pseudopregnancy.
Indomethacin treatment of rats during early pregnancy caused
a delay in implantation. The indomethacin treatment also caused a
significant reduction in uterine weight and in the number of implants
per uterine horn, on day 9 of pregnancy compared to controls. Plasma
progesterone levels were significantly lower on day 6 to 9 of
pregnancy in indomethacin treated animals compared to controls. The
possible roles of prostaglandins and the involvement of other
factors, in implantation is discussed.
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List of Prostaglandins and Thromboxanes and Metabolic Pathways of
Arachidonic Acid.
The following is a list of the prostaglandins end thromboxanes
mentioned in the text of this thesis together with their structures.
Structures of arachidonic acid, 15-hydroxyarachidonic acid and
15-hydroperoxyarachidcnic acid, 8, 11, 14 eicosatriencic acid and its
corresponding 15-hydroxy and 15~hydrcperoxy compounds are also given.
Hatched lines indicate bend orientations below the plane of the paper,
thickened lines, orientation above the plane of the paper. A wavy
line indicates that the bond orientation is not known or can be in
either plane.
The list is followed by Figs.1-4 representing the metabolic
pathways of arachidonic acid. Fig.4 represents the metabolic pathway
proposed recently by Jones, Kerry, Peyser, Walker and Wilson (1979)
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The involvement of prostaglandins in various reproductive
processes, has been the subject of much discussion over recent years.
The work reported in this thesis deals with their particular rcle(s)
in the processes of parturition and implantation in the rat.
Karim (1966) was the first to observe increased levels of a
substance, with properties similar to those of prostaglandin F^ ,
(PGF^) in the peripheral venous blood of women during labour. He
also claimed that the highest concentrations were found one minute
prior to and during a uterine contraction (Karim 1968), although
subsequently Sharma, Hibbard, Hamlett and Fitzpatrick (1973) re¬
ported that the maximum concentrations occur after a contraction.
Brummer (.1972) has also reported that the concentration of F type
prostaglandins in peripheral venous serum, increase during labour.
These latter results mu3t be treated with caution however, as the
contribution of ^^2 formed by platelets and blood cells during
isolation of serum and also any possible non-enzymic cyclization of
polyunsaturated fatty acids, is difficult to estimate. Salmon and
Amy (1973) have found that PGF2 ^levels, measured by radio-immuno-
assay (RIA) increase during labour in women, but Jouvenaz, Nugteren
and Van Dcrp (1973) were unable tc detect PGF2 ^ by an electron
capture method. The plasma levels of PGF2^ and its major meta¬
bolite 15-keto, 13,14-dihydro-PGF2(PGFfi), h ave been measured
in women by Green, Bygdeman, Toppczada and Wiquist (1974) prior to
and during normal and oxytccin-induced labour, using the technique
of gas chromatography combined with mass-spectrcmetry (GC-MS). They
found that levels of PGFM were low during the last month of pregnancy
but increased significantly over the 15 hr prior tc parturition and
showed a 10-30 times increase during active labour. The plasma
levels did not vary significantly in relation to contractions, but
were related to the degree of cervical dilation. Levels were found
to fall after parturition. During oxytocin-induced labour, the
PGFM levels were also high, but showed no relationship to the progress
of labour. The authors did not confirm that peripheral levels of
PGF2^increased during labour in women, but suggest that the increase
in the PGF metabolite levels reflect an increase in ^^2^ output
from the uterus and that the PGF2 is metabolised by the lungs before
reaching the peripheral circulation. They further suggest that PGF20( may
10 -
be important for the maintenance and acceleration of uterine
activity during the active stage of labour. Karim and Devlin
(1967) have previously proposed the decidua as the main site of
prostaglandin production, but recent studies (Thorburn: In Press)
have indicated that the amnion and decidua are the major sites of
prostaglandin synthesis in women.
Prostaglandin F output from the uterus has been found to
increase prior to and/or during parturition in the goat (Currie,
Wong and Thorburn 1973), cow (Fairclcugh, Hunter and Welsh 1975)
and sheep (Liggins and Grieves 197l). Peripheral plasma levels
of PGF2 ^ in the rabbit tend to increase during the last week of
gestation (Challis, Davies and Ryan 1973). Peripheral plasma
levels of PGF2 ^ in the pregnant rhesus monkey are low and do not
show any significant change near term (Challis, Robinson and
Thorburn 1977). However, during the last 10-20 days before
delivery there is a progressive increase in the concentration of
PGF2^ and 15-keto,13,14-dihydro PGF2Q< in samples of amniotic
fluid (Challis, Hartley, Johnson, Patrick, Robinson and Thorburn
1977). Production of is thought to be by the decidua
and amnion (Thorburn: In Press). Labhsetwar and Watson (1974)
have shown that the level of PGF2 ^ in uterine venous blood from
pregnant rats on days 21 and 22 are higher, compared to levels on
days 18 and 20 (day 22 being the day of parturition). Shaikh,
Saksena,(1977), observed a dramatic increase in uterine venous
levels of PGF20< on day 20 in rats compared to previous days of
pregnancy. This was followed by a fall on day 21 and another
large increase on day 22.
Less work has been performed to measure levels of prosta¬
glandin E2 (PGE2) at term, although Heterlendy, Woods and Jaffe
(1973) did report an increase in peripheral venous blood levels
of POE2 during labour in women. Plasma levels of POE2 in the
rhesus monkey did not show any changes near term, as was found
for ^^2^ (Challis, Robinson and Thorburn (1977). Shaikh and
Saksena (1977) found that in the rat PGE2 showed the same pattern
as PGF2 ^ in uterine venous blood i.e a sharp increase on doy 20
followed by a fall on day 21 and a second rise on day 22 of
pregnancy.
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It is possible to delay the onset of parturition and to
prolong its duration by the administration of drugs which inhibit
prostaglandin synthesis. Indomethacin, administered to pregnant
rabbits from day 20, prolonged the gestation period by two days
(Challis, Davies and Ryan 1975). Gestation length is also increased
in the hamster with indomethacin, given twice daily on days 14-16
of pregnancy. Injection of PGF2 , into these animals on day 15
was found to advance the onset of parturition (Lau, Saksena and Chang
1975). Neither indomethacin nor PGF0 had any effect on theZ CK '
duration of parturition. In retrospective studies of pregnant wcmen,
aspirin-like drugs have been shown to produce increases in gestation
length and the length of parturition (Lewis and Schulman 1973;
Collins and Turner 1973).
In 1972 Aiken demonstrated that the oral administration of
indomethacin and aspirin, to rats, over the last few days of gestation
would lead to a prolonged parturition. Chester, Dukes,Slater and
Walpole (1972), using a similar dose schedule of indomethacin to that
used by Aiken, showed a delay in the onset of parturition. This also
occurred with fenclozic acid, another prostaglandin (PG) synthetase
inhibitor (Sykes and Maddox 1972), and naproxen also was found to
prolong pregnancy and delay labour in the rat (Csapo, Csapo, Fay,
Henzl and Salau 1973). Dunn, Humphries, Judkins, Kendall and
Knight (1973), found that injection of an antibody to PGF2on day
17 of pregnancy in the rat, prolonged gestation by more than 24 hrs.
All treated animals eventually delivered, but the excessive loss of
blood and foetal mortality observed were similar to that found in
animals treated with aspirin or indcmethacin. It is clear,
therefore, that PGF2 ^ and possibly PGE2 are released from the
pregnant uterus at term in several species and are necessary
for the normal occurrence of parturition.
It would be useful at this point to consider the control
(hormonal or otherwise) of prostaglandin production in the different
species, at or near term.
In most mammalian species, the maintenance of pregnancy is
dependent on progesterone production. In a number of species, e.g
goat, ccw, pig, rat, the maintenance of adequate progesterone levels
is dependent on a functioning corpus luteum throught pregnancy,
- 12 -
and therefore delivery is dependent on luteal regression, since
progesterone levels have to fall in these species if parturition
is to take place. In the sheep, however, progesterone from the
corpus luteum is only vital up to day 50 of pregnancy and from
then on, placental production is adequate to maintain pregnancy.
At term, the foetus modifies placental steroidogenesis to effect
its own delivery. The guinea pig is only dependent on the corpus
luteum for progesterone up to day 25 of pregnancy and progesterone
levels do not fall prior to parturition in the guinea pig, which is
similar to women in this feature and unlike other species (see
Horton and Poyser 1976).
In the sheep, as in the goat, cow and pig, the onset of
parturition depends on the presence of a foetGl pituitary and an
active foetal pituitary-adrenal axis (see Thorburn, Challis and
Currie 1977 for review of evidence). During the last 10-15 days
pre-partum in the sheep, there is a gradual rise in foetal plasma
Cortisol levels followed by a more rapid rise over the last 2-3
days of gestation (Thorburn, Nicol, Bassett, Shutt and Cox 1972).
This is accompanied by a fall in maternal progesterone levels over
the last 4 days of gestation (Bassett, Oxborrow, Smith and Thorburn
1969) and an increase in unconjugated oestrogen levels during the
last 24 hr of pregnancy (Thorburn et al 1972; Challis 197l). The
increase in foetal Cortisol levels at term is apparently dependent
on a trophic drive from the foetal pituitary and maturational
changes in the foetal adrenals (Liggins 1973). Prolactin levels
and foetal Cortisol levels show a direct correlation during the last
30 days of gestation, suggesting prolactin may be important in
promoting growth of the foetal adrenals and the stimulation of
steroidogenesis, but the involvement of other pituitary hormones
cannot be excluded. The PGE concentration in foetal plasma
increases near term and there is evidence to suggest that PGE
acts to augment the effects of ACTH on steroidogenesis in the foetal
adrenal. ^^2 may °iSo stimulate release of pituitary hormones
in the foetus (Lewis, Challis, Robinson and Thorburn 1976). The
evidence suggeststhat the increase seen in foetal Cortisol levels
in sheep, is responsible for the fall in progesterone and
rise in oestrogen seen in the maternal plasma. The rise in cortisol
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induces the 17c*. -hydroxylase and C17-20 lyase enzymes in the placenta
and thereby stimulates the formation of androgens from progesterone
and pregnenolone. The androstenedione formed is converted into
oestrogens by aromatase enzymes (Thorburn, Challis and Currie 1977).
This mechanism explains the fall in maternal plasma progesterone
before delivery and the increasing concentrations of 17o< 20 ex. -
dihydroxy-pregn-4-en-3-cne and androstenedione in the uterc-cvarian
vein (Liggins, Fairclough, Grieves, Forster and Knox 1977). These
changes result in an increase in "free" oestradiol 17p in maternal
plasma during the 24 hr prior to delivery. This elevation in
oestrogen levels is associated with the increase in PGF levels in
the utero-cvarian venous blood and the onset of active labour
(Challis, Harr ison, Heap, Hcrton and Poyser 1972; Thorburn et al
1972). It has been suggested that oestrogen acts on uterine
oestrogen receptors to stimulate PGF2 ^ release as measured in the
uterine vein (Thorburn and Challis 1978). After this initial
release cf PGF2 , there is a much larger release of PGF2 ^
during active labour. This is due to stretching of the cervix
and vagina, which, via a nervous reflex releases oxytocin,which
then acts back on the uterus to cause the second release of PGF2,.
(Flint, Forsling and Mitchell 1978; Liggins et al 1977).
In the goat, ccw and pig, the ccrpus luteum is the^site cf
progesterone synthesis throughout pregnancy (see Hcrton and Poyser
1976; Thorburn et al 1977). Re gression cf the ccrpus luteum
and a consequent decline in plasma progesterone levels precedes
the development of uterine activity and normal delivery, although
in the pig, progesterone withdrawal is not complete at delivery
(Rcbertson and King 1974). Any "message" from the foetus in
these species must initially act to cause luteal regression.
In the goat, there seems to be trophic support of the ccrpus
luteum from the maternal pituitary and from the placenta, possibly
by a placental lactogen, as this hormone appears in the maternal
circulation around day 60 and increases up to day 125 of
pregnancy (Currie and Thorburn 1977). Levels tend tc fall
progressively over the last 15 days of pregnancy. It may be that
the fall in lactogen leads to a decrease in trophic support of the
corpus luteum and, therefore, a decline in progesterone production
which may facilitate the later release of PGF0 which' z cx
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ensures irreversible luteolysis. PGF is found in the uterine
vein of the goat, up to 24 hr prior to the final abrupt fall in
progesterone levels, in concentrations which are luteolytic
(Currie and Thorburn 1977). The stimulation for PGF appears to
be oestrogen (oestrone and ©estradiol 17 e< ) which show a rapid
rise in the maternal plasma during the last 4-5 days prior to
delivery (Thorburn et al 1972). The oestrogen rise could be due
to an increase in precursors from the foetal adrenal. Increases
in PGF production may involve oestrogen induced changes in the
stability of lysosomal membranes in the maternal placenta, its
action releasing hydrolases, consistent with the idea of oestrogen
causing separation of the placenta and membranes (Currie and
Thorburn 1977). However, like the sheep, there appears to be
two surges of PGF2 ^ . The smaller initial one is concerned
with luteolysis, while the second,large peak is probably due to
a nervous reflex and oxytocin release, as .in the sheep. The
second, but not the first peak can be blocked by continuous
progesterone administration (see Norton and Peyser 1976).
In the cow, there is a gradual fall in plasma progesterone
levels over the last 20 days and a more rapid fall 2-3 days before
parturition (Donaldson, Bassett and Thorburn 1970). PGF levels
in the utero-ovarian vein, increase 24-48 hr before delivery and
are closely related to the sharp fall in plasma progesterone
(Thorburn et al 1977). Urinary cestrogens rise progressively
during the last month of pregnancy and plasma oestradiol levels
show a similar rise during the last 30 days and fall post-partum
(Smith, Egerton, Hafs and Convey 1973). The likely major site
of oestrogen production in the cow, is the placenta (see Thorburn
et al 1977). PGF may be the luteolytic factor in the cow, as its
administration during early pregnancy or near term, causes luteclysis
and abortion (Zerobin, Jochle and Steingruber 1973; Lamond,
Tomlinson, Drost, Henricks and Jochle 1973).
In the pig, there is a gradual fall in progesterone levels
for 20-15 days before parturition and a more rapid fall over the
last 2 days (Killian, Garverick and Day 1973). Urinary oestrogens
rise during pregnancy and unconjugated oestrogens and oestrone
sulphate in maternal plasma rise during pregnancy, but ujr\*\a*^ WoeVs,
<4o ckecVivve
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post partum (Robertson and King 1974)• PGF is luteolytic in the
pig and parturition can be induced with PGF^ ^ (Diehl, Godke,
Killian and Day 1974) and its analogue I.C.I. 79959 (Ash and Heap
1973). It therefore seems reasonable to suppose that luteolysis
at term and parturition in the pig is dependent on increased uterine
PGF2<^ output.
Parturition in the pig,like the sheep, goat and cow is depend¬
ent on an intact foetal pituitary-adrenal cortex axis and the hormonal
changes initiated in the foetus eventually leads to increases in
uterine PGF„
^ output. However, parturition in the rat is not
apparently dependent on hormonal changes initiated in the .'foetus since
embryectomy between days 9 and. 15 leads to delivery of the placenta at
the correct time (Selye,Collip and Thompson 1935)• In the rat, as in
the goat, cow and pig, the corpus luteum is the source of progesterone
throughout pregnancy. In the pregnant rat, the corpus luteum receives
trophic support from the maternal pituitary up to day 11 and then from
a placental luteotrophin, up to day 15. There is a small decline in
progesterone levels from day 15 to 19» due to decreased production of
H
placental luteotrophin after day 15. This is followed by a more rapid
fall in progesterone up to day 22, the day of parturition (Csapo and
Wiest 1969; Fepe and Rothchild 1972). There is no decrease in the size
of corpora lutea, but the fall in progesterone is accompanied by a rise
in 20 *-dihydroprogesterone, thus implying a functional luteolysis,
involving a redirection of synthesis. Hence progesterone would be
converted to 20ck-dihydroprogesterone by the enzyme,20<K-hydroxysteroid
dehydrogenase, the activity of which increases before parturition
(Wiest 1970). Kuhn and Briley (1970) however, have proposed an alter¬
native pathway of pregnenolone metabolism in the rat ovary before term,
which contributes to the observed fall in plasma progesterone and rise
in 20c<-dihydroprogesterone. They showed a marked increase in ovarian
20®<-hydroxysteroid dehydrogenase activity one to two days before
parturition and proposed that this enzyme converts pregnenolone to
pregnenediol, which then competes with progesterone for 5 JB-hydroxy-
steroid dehydrogenase, to form 20®<-dihydroprogesterone.Oestrogen
output from the maternal ovaries is low until a few days prior to
parturition (.Shaikh 1971) .As oestrogen levels rise, the level of PGFg^
in the utero-ovarion vein increases (Shaikh,Naqvi and Saksena 1977)
as.does the prostaglandin synthesising capacity of the uterus
in -vitro (Vane and Williams 1974). The evidence suggests
that the rise in oestrogen is the stimulus for the increase in
- 15a
PGF^^ synthesis and release, as ovariectomy on day 16 followed
by oestrogen treatment, induces premature delivery, an effect
blocked by naproxen (a prostaglandin synthesis inhibitor). The
action of prostaglandins in this instance is clearly a direct
one on the pregnant uterus as no corpora lutea are present (Csapo,
Csapo, Fay, Henzl and Salau 1973). The stimulus for the rise in
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oestrogen which occurs prior to parturition is from the pituitary,
as hycphysectomy in late pregnancy prevents the rise (Wayneforth
and Robertson 1972). The increase in PGF0 release subsequent
to oestrogen increasing, moy cause the second, rapid fall in
progesterone levels seen from day 19, due to a luteclytic action
on the corpus luteum. The rapid decline in progesterone can be
blocked by indomethacin treatment (Strauss, Sokolski, Caploe, Duffy,
Mintz and Stanbough 1975). Experiments performed by Louis,
Lawrence, Becker and Borden (1978) suggested that the pelvic nerves
participate in the events leading to parturition in the rat. Pelvic
neurectomy on day 8 prevented the more rapid fall in plasma proges¬
terone which occurs on day 19 of pregnancy, although levels did
gradually fall later. Parturition was also prevented on day 22.
Pelvic neurectomy also prevented the rising uterine plasma PGF
levels which normally occurs on the day of parturition. The
increases in levels of 20 °< -hydroxyprogesterone seen at parturition
were not blocked. These results suggest that the pelvic nerves
have some control on the increased release of PGF2<=><. at parturition.
The foetus of the Rhesus monkey may play an active role in
initiating its own delivery, but the mechanism is different to
these discussed previously for other species (for evidence see
Thcrburn: In Press). Before delivery, only slight increases in
maternal plasma oestradiol and progesterone are observed. However,
amniotic fluid levels of oestrone, oestrone sulphate, PGF0 and/ G<
13,14-dihydrc-15-keto PGF2 rise,along with progesterone and
androstenedione, during the last 10-20 days of pregnancy (Challis,
Hartley, Johnson,Patrick,Robinson and Thorburn 1977). The increases
in progesterone and androstenedione are considered as an expression
of an increase in foetal adrenal activity which leads to a rise in
amniotic oestrogen, which in turn stimulates PG production by the
decidua. Oestrogen is thought to act by labilising lysosomal
membranes, releasing phospholipase (P^2^ w^ich acts on phosphol¬
ipids to release the prostaglandin precursor, arachidonic acid
(Challis, Robi nson and Thorburn 1977).
It is thought that prostaglandin synthesis is actively sup-
ressed during pregnancy by the foetus and that parturition occurs as a
removal of this supression, although the mechanism is uncertain (Robinson,
Challis, Chapman and Thorburn 1977). The tfephoblast and membranes
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have been implicated in the production of a number of materials,
e.g. chorionic gonadotrophin, renin, prolactin and one or more
substances may be involved in prostaglandin supression. The
increase in oestrogens may also increase oxytocin receptors in the
membranes and decidua^and oxytocin then stimulates prostaglandin
synthesis by the amnion and decidua, which triggers parturition
(Thcrburn: In Press).
As in the case of non-human primates, the human shows no
abrupt changes in maternal oestrogens or progesterone prior to
the start of labour. Evidence for the human has been reviewed
by Liggins, Forster, Grieves and Schwartz (1977), The maintenance
of the pregnancy is dependent on placental hormones and the corpus
luteum has no function after the second month of pregnancy (Csapo,
Pulk.kinen, Ruttner, Sauvage and Weist 1972; Csapo,Pulkk««en and
Weist 1973). The foetus appears to play a relatively minor
role in the initiation of parturition. There is no strong
evidence for a rise in foetal Cortisol levels before the onset of
labour and no evidence for an action of Cortisol on the placenta,
as is the case in the sheep. Cortisol is unlikely to feature as a
physiological triggering mechanism in human labour but it may
share in a more complex endocrine trigger.
There is no evidence in women for thewithdrawal of a uterine
inhibitory factor (the function of which would be to prevent uterine
activity), for the initiation of labour^and although betamimetics
such as salbutamol are very effective in inhibiting labour (Liggins
and Vaughn 1973), there is no evidence that the uterus is normally
strongly inhibited by catecholamines. Maximum levels of oxytocin
are found during the second stage of labour and ethanol is thought
to inhibit labour by inhibiting oxytocin release from posterior
pituitary (Fuchs, Fucbs,Poblete and Risk 1967; Mantell and Liggins
1970). The evidence suggests that oxytocin is not involved in
the initiation of human parturition, but has a role in the main¬
tenance of labour once it has been established. There may be an
interaction of oxytocin and prostaglandins, as intravenous infusion
of subthreshold doses of prostaglandins enhance the oxytocin
response (see Liggins et al 1977).
Prostaglandins are released into the maternal circulation
(Green, Bygdeman, Toppozada and Wiquist 1974) and amniotic fluid
during labour (Salmon and Amy 1973; Kierse, Flint and Turnbull 1974)
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but there is no unequivocal evidence of their involvement in the
initiation of labour. It has yet to be shown that there is an
increased release of, or enhanced uterine response to, prosta¬
glandins immediately prior to the onset of labour. However,
significantly higher levels of PGF2(p^ have been found in the
amniotic fluid during early spontaneous labour than in early
induced labour, although uterine activity was higher in the latter
group (Hillier, Calder and Embrey 1974).
The decidua and foetal membranes are the sites favoured
for prostaglandin production; prostaglandin release from these
tissues would not be due to contractile activity, as may be the case
for the uterus. The arachidonic acid content of decidua and
foetal membranes is high and it is incorporated into foetal membranes
in preference to other unsaturated fatty acids (see Liggins et al
1977). PLA2 activity of the reproductive tissues during pregnancy
is highest in the deciduutri and amnion (Grieves and Liggins 1976).
There is litile evidence in women that PGF2 ^ synthesis is
stimulated by changes in plasma levels of cestrogens and progesterone.
Evidence is accumulating in support of the "lysosomal theory"
of Gustavii (1975). In this hypothesis, a key role in labour
initiation is attributed to lyscmomes. The deciduum becomes rich
in lysosomes which are maintained in a stable state during
pregnancy by the presence of stabilizers, particularly progesterone.
The onset of labour (or abortion) may be precipated by a labilising
influence causing'leak"of lysosomal enzymes, including PLA2 into
the cyctoplasm. The PLA^ acts on phospholipid, releasing
arachidonic acid which in turn leads to increased prostaglandin
production. Prostaglandins diffuse partly to the myometrium which
they activate and into amniotic fluid where a rise in concentration
is observed.
Liggins, Forster, Grieves and Schwartz (1977) suggest that
the foetal membranes and deciduum may function as a unit, the
membranes serving as a substantial source of arachidonic acid for
prostaglandin synthesis in the deciduum and possibly the chorion.
The factors which promote the selective incorporation of arachidonic
ocid into phospholipids and stimulate its release are unknown. It
has been proposed that a specific progesterone-binding protein found
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in the cytcsol of human foetal membranes, in low concentrations
before the 38th week of pregnancy and in much higher concentra¬
tions at term, binds progesterone, thus removing its stabilizing
influence o'n lysosomes. Therefore, there is a local with¬
drawal of progesterone which is independent of maternal plasma
levels^ ( Schwartz, Vanatta, Siiteri and MacDonald , 1974). This
hypothesis of a local removal seems more acceptable than that
proposed by Gustavii (1975), who attributes the initial lysosomal
labilization to a rise in oestrogen and fall in progesterone levels.
There is no evidence to support such abrupt changes in maternal
levels of these steroids at the start of labour. The causes for
the accumulation of the progesterone-binding protein proposed by
Schwartz and his co-workers is not known. It seems that labour,
in the human therefore, is initiated by a maturational signal
arising from the foetal membranes and interacts with the deciduum.
The foetal and maternal hormones play only a minor part, adding
accuracy to the exact timing of parturition.
It is clear that one or more prostaglandins are released
at term from the pregnant uterus and/or its contents, under the
control of specific hormonal changes. These may be well defined
as in the sheep and goat or less clear as in the primates. Since
prostaglandin level® are elevated at term, it is assumed that
they have a function in the parturition process and several
roles have been postulated. A luteolytic actio" at term has
been proposed, which leads to a fall in plasma progesterone
levels followed by parturition. Administration of PGF2^ to
goats during the final period of gestation, leads to a premature
decline in progesterone levels and the induction of parturition
(Currie and Thorburn 1973). Administration of PGFp^ to pigs
in late pregnancy produces similar results (Diehl, Godke, Killian
and Day 1974), and premature parturition can be induced with the
PGF2 ^ analogue I.C.I.79939, it is presumed by a luteclytic
action (Ash and Heap 1973). In the cow, increases in the ratio
of plasma levels of oestrogen to progesterone over the last period
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of gestation (Fairclough, Hunter and Welsh 1975; Henricks, Dickey,
Hill and Johnson 1972; Robertson 1974), ha\ebeen suggested as
being responsible for on increased output of PGF^^ which in turn
causes a decline in progesterone levels by causing luteol
regression (Fairclough et al 1975). Treatment of rats on day 18
of pregnancy with PGF2 D,, leads to a decline in progesterone and
premature parturition (Buckle and Nathanielsz 1973).
There is much evidence which suggests that prostaglandins
contribute to the expulsion of the foetus by acting as uterine
stimultants. In the goat there is a small rise in PGF2<=< in
the uterine vein during the 24 hr prior to normal parturition
which is associated with luteolysis, but this small increase is
followed by a larger increase immediately prior to birth and this
second release may be involved in uterine contractions (Currie,Wong,
Cox and Thorburn 1973; Thorburn, Nicholl, Bassett, 5hutt and Cox
1972). S imilarly in the rat, there is a rise in utero-ovarian
vein levels of PGF and PGE on day 20 of pregnancy followed by a fall
on day 21 and a second rise on day 22. Plasma progesterone levels
fall on day 20 and parturition occurs on day 22 (Shaikh, Naqvi and
Saksena 1977). Premature parturition can be induced in guinea pigs
with PGF2 c< , probably by a direct stimulant action on the uterus
(llingworth, Challis, Ackland, Burton, Heap and Perry 1974). In
pregnant women, E and F prostaglandins have a direct oxytocic effect
on the uterus (Karim 1972; Wiquist, Bygdeman and Toppozada 1973) and
Karim and Hillier(l970) proposed that prostaglandins may be involved
in spontaneous abortion, although whether prostaglandin production
and release induced contractions, or was a result of contractions,
was unclear. Intravenous PGE0 or PGF2^ during first or second
trimester of pregnancy, causes abortion (Karim and Filshie 1970a;1970b;
Roth-Brandell, Bygdeman, Wiquist and Bergstrom 1970). Extra
amniotic injection of hypertonic saline to women, 18-22 weeks
pregnant causes the appearance of high concentrations of PGF^ ,..t
in the amniotic fluid, prior to abortion (Gustavii and Green 1972).
Interest has been focused recently on the actions of prosta¬
glandins on the uterine cervix. Najak, Hillier and Karim(l970)
demonstrated that the non-pregnant human cervix exhibits spontaneous
contractility in vitro and that PGE2 caused marked relaxation, while
the effects of PGF2 r< were more variable. Green et al (1974)
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noted that the plasma levels of the PGF2 ^ metabolite, 15-keto-
13,14-dihydro-PGF2 , were directly related to the degree of
cervical dilation in women during labour. Before the process of
parturition can proceed, it is necessary for the cervix to elongate
and soften, thus allowing the foetus to pass through. In cases
where artificial induction of labour is necessary, enforced
mechanical dilation can cause a subsequent increase in the rate of
cervical incompetence, spontaneous abortion and still birth.
Cervical dilation has been successfully achieved prior to labour
induction using oral PGE2 (Pearce 1977; Golbus and Creasy 1977').
Cervical dilation is also a pre-requisite of abortion and the same
problems arise as have been discussed for labour induction.
Dilation has been achieved by oral PGE2 (Van den Bergh, Szabo,
Szantagh 1976), vaginal PGF2 ^ (BrePner, Dingfelder, Staurovsky
and Hendricks 1973), extra-amniotic PGF2^ and PGE2 (Wiquist,
Bequin, Bygdeman, Ferstrom and Toppozada 1972) and also by vaginal
administration of PGF2 ^ analogues (e.g 15(s) - 15 methyl PGF2rV
methylester; Zormethangi, Agarwal, Puni, Laumas, Soraya and
Hingorani 1977). ^^2 seems more potent than as
a cervical relaxant. In the late pregnant rat, the exten¬
sibility of the cervix in vitro, was found to be increased by prior
administration of or ^^2 *° anim°l (Hollingsworth,
Isherwood and Gallincie 1.979). The authors suggest PGF2 ^
exerts its action indirectly by reducing progesterone levels ond/or
increasing the secretion of relaxin, but that PGE2 has other
mechanism (s) of action.
The role (s) of prostaglandins released from the rat uterus
at term, has been the subject of controversy. The capacity of
the uterus to synthesis prostaglandins Er, and F2^ increases near
term (Vane and Williams 1973; Harvey, Sneddon and Williams 1974;
Carminanti, Luzzani, Soffientini and Lerner 1976) and there is an
increase in the uterine vein levels of PGF prior to parturition
(Labhsetwar and Watson 1974; Shaikh and Saksena 1977). Flower (1977)
has reported that the activity of the enzyme metabolising PGF0cX
in the lungs of the rat, decreases before parturition, as a result
of a decrease in progesterone and an increase in oestrogen levels.
This may result in an increased circulating level of PGF2 ^ and
thus allow it to exert a spasmogenic effect on the uterus over a
longer period.
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Prostaglandin synthesis inhibitors will inhibit spontaneous
contractions of the pregnant rat uterus in vitro (Vane and Williams
1973) but contractions induced by oxytocin were not inhibited ,
although the dose response curve was shifted to the right in the
presence of the inhibitors. Contractions cculd be restored by
addition of or ^^2 fluid. Aspirin, indomethacin
and naproxen, will prolong parturition in the rat in vivo (Aiken 1972;
Csapo, Csapo, Pay, Henzl and Salau 1973; Chester, Dukes, Slater and
Walpole 1972) and abortion (Deis 1969) and premature labour
(Chatterjee 1976) can be induced in the rat with PGF2 <x
Fuchs (1972) however, could not induce parturition on day 22
of pregnancy (the day of delivery) with infusions of PGEj and PGF2 (X.
Infusions of oxytocin on day 22, did produce parturition. The
contractions caused by oxytocin were indistinguishable from
spontaneous contractions of labour (Fuchs and Poblete 1970). Infusion
of PGF2 ^ on days 18-20 induces premature delivery 36-44 hr later
(Fuchs and Mck 1973) and the authors suggest that this is due to a
fall in plasma progesterone levels brought about by the luteolytic
actions of PGF2 ^ , as the levels of PGF2 CN, used were lower than
those necessary for uterine stimulation. Other results have been
presented by Fuchs, Smitasiri and Chantharaksri (1976) as evidence
that PGF2 released from the uterus at term, has a luteolytic
function but is not involved in uterine contractions leading to
expulsion of uterine contents. Indomethacin treatment of rats
beginning on day 20 of pregnancy, delayed the onset of spontaneous
parturition by!4 hr. In vivo recordings of uterine contractions
however, were not inhibited by indomethacin. The delay in the onset
of parturition was accompanied by a similar delay in the decline
in plasma progesterone levels and the appearance of 20c< hydroxy-
dehydrogenase in the corpus luteum, indications of retarded
luteclysis, in indomethacin treated animals compared to controls .
Infusion of PGF2 ^ on day 21 reversed the effects of indomethacin.
Drugs which have been used to inhibit uterine prostaglandin
synthesis are not specific cyclo-oxygenase inhibitors (Flower 1974).
Other actions include phosphodiesterase inhibition as this type of
compound exerts unspecific inhibitory effects on muscle contractions
(Smith, Temple and Shearman 1975) and compounds such as indomethacin
and aspirin may affect the uterus by such a process.
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It is possible that oxytocin exerts part of its spasmogenic
action on the uterus by releasing prostaglandins, which in turn
cause contractions. Isolated non-pregnant rat uterine horns have
been shown to release prostaglandin-like activity on incubation
with oxytocin. (Chan 1974) and oxytocin-induced parturition is
inhibited in pregnant rabbits by administration of indomethacin
(Heterlendy 1973). However, Ishikawa and Fuc hs (1978) could not
show any effects of oxytocin on the accumulation of PGF from isolated
non-pregnant uteri from the rat and Roberts and McCracken (1976)
concluded that increased synthesis of PGF2 ^ was not an essential
intermediate in the activation of the myometrium by oxytocin, in
sheep.
Hence, much evidence has been accumulated which suggests a role
for the "classical" prostaglandins E2 and $2 oc / luteolysis,
uterine contractility and cervical ripening at term, in many species..
However, many of these studies were performed before it was realised
that PGI2 is a major substance produced by the uterus, Fenwick, Jones,
Naylor, Poyser and Wilson Q977) shewed PGI2 detected as 6-oxo-PGF^ ,
to be produced by homcgenates of pseudopregnant rat uteri. Many
studies have also overlooked the possible production of thromboxanes
during parturition. Section II of this thesis deals with PGIo and
thromboxane production, as well as PGE2 and PGF2 x by the pregnant
rat uterus, at term.
Prostaglandins have recently been implicated as having a
function in the process of implantation, although studies have so far
been restricted to a few species only i.e. mice, rats, rabbits and
hamsters. It is more difficult to prove an involvement of prosta¬
glandins in implantation because the site of production is also the
site of action, unlike processes such as luteolysis, for example,
where the prostaglandins have to be transported to the site of action
and the opportunities for experimental manipulation are therefore
greater.
There is evidence in the rat and rabbit that prostaglandins
are involved in decidualization of the uterine endometrium. PGE
levels were found to be significantly higher in the artificially
induced, decidualized horns of rat uteri, compared to control horns
(Anteby, Bauminger, Zor and Lindner 1975). P rostaglandin synthetase
levels were also higher in the decidualized horn. PGF levels on the
other hand, were not significantly different from control levels and
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were lower than PGE levels. However, PGF2^ has been found to
induce decidualization when instilled into the uterine lumen of
prepubertal rats maintained on progesterone (Sonanes, Baulieu and
Le Gascogne 1976). Scratching the endometrium in prepubertal rats
maintained under the same hormonal conditions elicits the decidual
response and this can be prevented by indomethacin treatment.
Tobert (1976) also found that the olive oil-induced decidual cell
reaction was significantly reduced by indomethacin, when given before
or after the oil stimulus. Hoffman, Strong, Davenport and Frolich
(1977) have found PGEp, PGF2^ and arachidonic acid will cause
decidualization when instilled into the uterine lumen of pseudopregnant
rabbits. ^^2 was mos^ potent.
Prostaglandin production by the pseudopregnant rat uterus
in vitro, has been shown by Fenwick et al to reach a peak on day 5
(the day of implantation in the pregnant rat). PGE and PGF levels
in the uterine venous plasma of pregnant rats also rise from days 1
to 5 and fall on day 6 (Shaikh, Naqvi and Saksena 1977). The levels
of PGF in the peripheral plasma of pregnant and pseudopregnant hamsters
show a peak late on day 4 (day 5is the implantation day)(Shaikh, Birchall
and Saksena 1975). Kennedy (1977) showed in the rat and Evans and
Kennedy (1978) in the hamster, that the concentration of PGE is
elevated, approximately two-fold in areas showing the "uterine dye
reaction" (which indicates the increase in vascular permeability at
the implantation sites) compared to non-dye sites(following intra¬
venous injection of blue dye on the day of implantation.
Treatment of rats, mice and hamsters with indomethacin, during
early pregnancy, leads to inhibition or delay of implantation. Treatment
of pregnant mice on day 1, 2, 3 or 4 inhibits pregnancy as determined
by the absence of implantation sites on day 8. (Lau, Saksena and Chang
1973). Chatte rjee (1973) found that treatment of rats on day 2 or 3
prevented implantation and this effect could be reversed by giving
human chorionic gonadotrophin on day 3 or oestradiol cyclopentylpro-
pionate on day 4. Indomethacin, given on the day of implantation
was found to cause delay (as determined by the appearance of the
uterine dye sites) in rats (Kennedy (1977) and hamsters (Evans and
Kennedy 1978). When given to rabbits on days 4-6 of pregnancy,
indomethacin was found to inhibit the uterine dye reaction normally
seen on day 6j-7 (Hoffman, Dipietro and McKenna 1978).
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Prostaglandins may also be important after implantation, in
the subsequent development of the foetus and maintenance of placental
function. Treatment of rabbits in early pregnancy with indomethacin
has been shown to produce inhibition of foetal development (Hoffman
1978) and resorption (El-Banna, Sacher and Schilling 1976; Saksena
and Harper 1974). Active immunisation of rabbits against PGE^ and
PGF2 ^ during early pregnancy was found to cause retardation of
embryonic growth, placental insufficiency and ultimately, foetal death
(Elzayat and Stylos 1974)t These effects on pregnancy development
must be carefully separated from effects on implantation when studying
the importance of prostaglandins, especially if animals are examined
several days after the expected time of implantation. Studies which
involve the examination of the uterus for "dye reaction sites" are
particularly useful for this reason.
Aspirin-type drugs will block phosphodiesterase in concentrations
slightly higher than those required for inhibition of prostaglandin
synthesis (Flower 1974) and therefore, studies involving these compounds
should take into account a possible effect on cyclic-3* 5'-adenosine
monophosphate (cyclic AMP) levels. Any inhibition of phosphodies¬
terase will lead to an increase in cyclic AMP levels. Increasing the
level of cyclic AMP is reputed to prevent histamine release from mast
cells by inhibiting calcium uptake (ishizaka, Ishizaka, Orange and
Austen 197l). A histamine involvement in implantation in mice, rats
and rabbits has been implicated. Block of implantation in the mouse,
obtained with indomethacin, could be reversed in 60?" of animals treated
with PGE2 and/or PGF2 x (Sak sena, Lau and Chang 1976). Oestrogen-
induced implantation in the rat, could not be obtained in uteri which
had been pre-frozen but treatment of such uteri with a histamine
infusion did induce implantation^ (Ferrando and Nalbander 1968).
Disodium chromoglycate (intal) when instilled into the uterine lumen
of pregnant rabbits decreased the number of implants and this action
was reversed by the simultaneous instillation of histamine (Dey,
Villanenva, Chien and Crist 1978). Intal is reputed to prevent
histamine release from mast cells by inhibiting calcium uptake (Brogden,
Speight and Avery 1974). Hence indomethacin may increase cyclic AMP
levels (by inhibiting phosphodiesterase) and thereby prevent histamine
release, in addition to inhibiting prostaglandin synthesis. Consequently
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replacement therapy with both histamine and prostaglandins would be
required to achieve implantation in indomethacin treated animals, as
has been shown in the mouse (Saksena, Lau and Chang 1976).
Contrary to the above discussion, which implies that an increase
in cyclic AMP.is detrimental, there is evidence that cyclic AMP may be
involved in implantation. Implantation can be induced in pregnant
ovariectomised mice, maintained on progesterone by cyclic AMP,
(Holmes and Bergstrom 1975) and its dibutyryl analogue (Webb 1975).
In pregnant rats, treatment with the adenyl cyclase inhibitor,
alloxan, significantly reduces uterine PGE and PGF levels on days
5 and 6 compared to controls and this effect is reversed by concomitant
treatment with cyclic AMP, (Garg, DeSouza and Chaudhury 1979). This
suggests a stimulatory role for cyclic AMP on prostaglandin synthesis.
Conversely, however, Vesin, DoKhac and Harbon (1978) found that
treatment with the prostaglandin precursor, arachidonic acid, increased
cyclic AMP accumulation in oestrogen treated rats. It may be that
the time course of events during implantation is critical and that
histamine is released before a rise in cyclic AMP, which then acts as a
negative feedback, regulating histamine release.
When studying the effects of exogenous prostaglandins, for
example, as replacement therapy after indomethacin administration, care
should be taken in the interpretation of results. Effects may be
observed which are a consequence of actions of prostaglandins such as
luteolysis or effects on egg transport (Labhsetwar 1972). Administration
of PGE2 or P6F2 ex Pregnant rats has been shown to prevent
implantation (Batto and Martini 1975), probably by Gctivation of
uterine contractility.
From experimental evidence, it seems that oestrogen is
responsible for the initiation of implantation. In the pregnant
mouse, there is a rise in circulating oestrogen on day 4 (McCormack
and Greenwald 1974), which is followed by increased uterine sensitivity
to formation of decidual tissue (Hetherington 1968) essential for
implantation (Humphrey 1967). In pregnant rats there is a surge of
oestrcne end oestradiol in peripheral plasma detectable early on day 4
(Shaikh 197l) preceding implantation cn day 5. A small rise in plasma
oestradiol up tc day 4 is also seen in the pseua'opregriant rat end so is
independent of the blastocyst (Welschen, Osman, Dullaart, De Greef,
Uilenbroek and De Jong 1975). Similarly, in pregnancy and pseudo-
pregnancy in the hamster, oestrone and oestradiol levels in ovarian
venous plasma increase from day 1 to 4 and fall on day 5 (the day of
implantation)y (Shaikh et al 1973). Implantation can be initiated
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in pregnant ovariectomised mice (Saksena et al 1976), and rats
(Ferrandc and Nalbander 1968), maintained on progesterone by admin¬
istration of single dose of oestrogen. In pregnant, ovariectomised
rabbits, maintained on progesterone, implantation proceeds without
oestrogen administration, but can be prevented by the anti-oestrogen
drug Cl-628 (Dey, Dickmann and Sen Gupta 1976). It has been suggested
that oestrogen, produced by the rabbit blastocyst is necessary for
implantation and indeed the rabbit blastocyst has been shown capable
of producing oestrogenic steroids and also to contain oestrogen
(Dickman,Dey and Sen Gupta 1975). It has also been shown in the
ovariectomised hamster, that oestrogen is not required for implanta¬
tion (Harper, Dcwd and Elliott 1969). The blastocyst of the pig has
been shown to synthesize oestrogen (Perry, Heap, Burton and Gadsby
1976; Flint, Burton, Gadsby, Saunders and Heap 1978) and this has
also been suggested for the hamster, mouse and rat (Dickman and Sen
Gupta 1974; Dey and Dickman 1974; Dickman 1976). So, although proges¬
terone is required for the maintenance of pregnancy, it seems that
oestrogen of maternal and/or foetal origin, is needed for the
initiation of implantation. The anti-cestrogen drug ,Tamoxifen,
inhibits implantation in the rat, when given in early pregnancy
(Harper and Walpole 1967), A significant reduction in prostaglandin
synthesis by the uterus on day 5 of pseudopregnancy in the rat,
has also been shown when Tamoxifen is given on day 2 (Fenwick et al
1977). This infers that the oestrogen surge on day 4 is responsible
for the peak in prostaglandin production on day 5 of pseudopreanancy.
Cestradiol is known to stimulate the PGF2 synthesising capacity of
the uterus by increasing the amount of synthetase present (Ham,
Cirillo, Zanetti and Kuehl 1975) and oestradiol treatment of ovariec¬
tomised guinea pigs, produces similar results in vitro (Naylor and
Poyser 1975). Oestrogen has also been found to stimulate uterine
prostaglandin levels in hamsters (Saksena and Harper 1972) and mice
(Saksena and Lau 1973). In ovariectomised rats, mice, quinea pigs
and ewes, however, the optimum hormonal treatment for uterine
prostaglandin production was^ found to be a dose of oestrogen given
after a period of progesterone priming (Castracane and Graig-Jordan
1975; Saksena and Lau 1973; Caldwell,Tillson,Brock and Speroff
1972; Blatchley and Peyser 1974). These are the hormonal
conditions which exist in early pregancy in the mouse, rat and
hamster and hence it would seem logical to assume that
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the increased prostaglandin levels observed around the time of
implantation, are stimulated by an oestrogen surge of maternal and/or
foetal origin following a period of progesterone priming. In support
of this suggestion, it has been reported that the peak in PGF in
peripheral plasma on day 4 of pregnancy in the hamster is associated
with high levels of oestrone and oestradiol (Shaikh, Birchall and
Saksena 1973). Also, oestrogen-induced implantation can be inhibited
in mice by indcmethacin and this effect can be reversed by administra¬
tion of prostaglandins and histamine, as has been discussed previously.
Therefore, it seems that oestrogen stimulates increased production of
prostaglandins by the uterus and is involved in the events leading to
implantation of the blastocyst.
Oestrogen exerts other actions on the blastocyst and uterus
around the time of implantation, e.g. stimulation of RNA synthesis,
initiation of changes in the surface morphology of the preimplantation
blastocyst, promotion of cell division in the uterine stroma and
sensitisation for decidualization. These effects can be mimicked by
cyclic AMP (Mahla and Prasad 1970; Holmes and Bergstrom 1976; Webb 1977).
Oestrogen has been found to increase cyclic AMP levels in the uterus
(Szego and Davies 1967) and therefore, cyclic AMP may act; as a
"second messenger" for these oestrogen effects, as has been shown for
the stimulation of prostaglandin synthesis (Garg, De Souza and
Chaudhury 1979).
Experiments performed as described in Section III, have
investigated changes in the synthesising capacity of the rat uterus
for POE2, anc' around the time implantation. These
changes have been compared with those which occur in the pseudopregnant
animal. The effect of indomethacin on implantation and subsequent







Krebs' Solution 51 Acid Citroted Dextrose
Glucose 10g Glucose (Dextrose) 3g
Sodium Chloride 34.5g Disodium Hydrogen Citrate 2g
Sodium Bicarbonate 10.5g
Potassium Chloride 17.5ml )
Potassium Dihydrogen Phosphate Smlj^Q^ Solution
Magnesium Sulphate. 7 H2O 7 ml ) Tris Buffer pH 8.0
1M Calcium Chloride 12.5 ml 12g/l trihydroxymethylmethylamine
phosphate adjusted to pH 8.0 with
IN hydrochloric acid.
For Radio-Immuno-Assay (IA )
Diluent I
56 ml of 0.1M solution Sodium Dihydrogen Phosphate plus 34.5 Disodium
Hydrogen Phosphate in 51 distilled water pH 7.5. Plus O.lg/l Sodium
Azide (antibacterial) + lg/l Gelatin.
Diluent II
0.05M solution Trihydroxymethylmethylamine (Tris) Hydrochloride titrated
to pH 6.8 using concentrated Hydrochloric Acid (HCl).
Diluent III
0.05M Tris titrated to pH 8.0 using concentrated HCl.
Scintillation Fluid A
10.5g 2,5, diphenyloxazole (PP0) in a mixture of 1.51 Toluene and
0.91 2-ethoxyethanol.
Scintillation Fluid 3
4g/l 2-(4-tertbutylphenyl)-5-(4~biphenyl)-l, 3, 4, oxadiazole (Butyl F'BD)
in Toluene.
15-hydroperoxy arachidonic acid, the reported prostaglandin I2
synthesis inhibitor (Moncada, Gryglewski, Bunting and Vane 1976b),
was prepared by the action of soya bean lipoxygenase on arachidonic
acid (see Section I).
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Synopsis of Experiments
The experiments described in the following three sections were carried
o,ut using tissue obtained from female Wistar rats.Section I describes
the basic techniques used for the extraction, purification and assay
of all samples obtained. Section II described the experiments
performed to investigate the role(s) of prostaglandins in parturition
in the rat. The release of prostaglandins from the term pregnant
rat uterus in vitro and the effects of prostaglandins and prostaglandin
synthesis in- ibitors on the uterus, have been investigated. The female
rats were mated with male rats of the same breed, as described in
Section II. Methods.1. The experiments involved extraction and
measurement of prostaglandins released from the isolated, term pregnant
rat uterus, into the Kreb's bathing solution. The effect/ of adding
exogenous prostaglandins to th bathing fluid was investigated and also
the effect*/of prostaglandin synthesis inhibitors on the uterus and on
prostaglandin release from the uterus, at term.
Section III deals with the involvement of prostaglandins in
implantation in the rat. The capacity of the rat uterus to synthesise
prostaglandins in vitro around the time of implantation, during
pregnancy and also during pseudopregnancy has been investigated and
the two reproductive states compared. The extraction and assay of
prostaglandins from tissue homogenates has been performed in these
cases. The effects of inaomethaci.a (a prostaglandin cyclo-oxygenase
inhibitor) on implantation and on the subsequent development of the
pregnancy up to day 9 in the rat, has also been studied. Peripheral
plasma progesterone has been measured during pregnancy and pseudo-
pregnancy and also during pregnancy in indomethacin treated rats.
Female rats were mated with vasectomised or normal male rats
of the same breed, in order to achieve pseudopregnancy or pregnancy,
respectively, as described in Section III, Methods la and lb.
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1 . Solvent Extraction of Prostaglandins
The acidity of samples, from which prostaglandins were to be
extraced, was lowered to pH 4.0 with IN hydrochloric acid (HCl).
Each sample was then partitioned three times with two volumes of re¬
distilled ethyl acetate. The ethyl acetate fractions were combined,
evaporated to dryness in a rotary evaporator at 45°C and placed in
a dessicator under vacuum for 15 min. This extraction procedure
is summarised in Fig.5. The residues were redissolved in 10ml
redistilled ethyl acetate and stored,until assayed, at -20°C.
2. Recovery of Prostaglandins by Solvent Extraction from Krebs"
?oTu~ti"on
Three radioactive " counting standards" were prepared by adding
0.05pCi of radioactive prostaglandin to 10ml liquid scintillation
fluid A. At the seme time 0.125pCi was added to 20ml Krebs® solution
containing 2pg/ml of non-radioactive "cold" prostaglandin. The pH
of Krebs' solution was then lowered to 4.0 with IN HCl and the
solution was shaken three times with two volumes of redistilled ethyl
acetate. The ethyl acetate fractions were pooled, evaporated to
dryness at 45°C using a rotary evaporator and then placed in a
dessicator under vacuum for 15 min. The residue was redissolved in
0.6ml of methanol (MeOH) arid added to a vial containing 13ml liquid
scintillation fluid A. The three "counting standards" and the
vials containing extracted prostaglandins were then counted on a
liquid scintillation counter (Nuclear Chicago) for 2 min using an
external standard chemical ratios count. The number of disinte¬
grations per minute (DPM) of the solvent extracted radioactive
prostaglandin was compared to the DPM from the "counting standards".
From these values the % recovery from Krebs* solution of the
radioactive prostaglandin can be calculated.
% Recovery = Number DPM x 100
TCverage T5FM Counting Standards
This procedure was carried out for prostaglandin
^ (^^2ex. ^'
prostaglandin E2 (PGE2), prostaglandin D2 (PC^), 6-oxo-prostaglandin F^ ,
(6-oxo-PGF-j ) and thromboxane (TXE^).
The efficiency of the extraction procedure for progesterone
was determined by extracting a known amount of radioactive progester¬
one together with "cold" progesterone carrier by the methods described
subsequently and counting the extracted samples as described for









of the Mean (!
pGF2« 10 92 - 4.5
pge2 12 94 - 2.5
6-oxo-PGF.
1 <x
3 65 - 1.2
pgd2 12 91 t 2.5
txb2 10 94 - 5.5
Progesterone 12 93 t 1.6
As recovery of progesterone and all prostaglandins, with the
exception of 6-oxo-PGF^. , was over 90%, results were not corrected
for recoveries. A series of extractions were performed for
6-cxo-PGF.j ^ from pH 1.5 to pH 5.0, but 65% recovery was the maximum
which could be obtained and was recovered in the range pH 1.5 up to 4.5
The radio-immuno-assays for PGE,-,, PGF^^ and progesterone are we
established and therefore their accuracy is known to be satisfactory.
The radio-immuno-assay (RIA) for 6-cxo-PGF^ however has only recently
been established and therefore it was thought necessary to test the
accuracy of this assay by extracting known quantities of 6-cxo-PGF-j ^


















These results show that the RIA gives an accurate measure cf
the amounts of 6-cxo-PGF. present.I OS. 1
3. Extractions of Progesterone from Plasma Samples
Blood samples (2.0ml) were obtained from rats by cardiac punc¬
ture. Blcod was added to centrifuge tubes containing 10i,u/ml
heparin and was centrifuged at 600 x g for 10 min using a bench
centrifuge (MSE).
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Fig.5. Sclvent Extraction cf Prostaglandins
Sample
pH 4.0
Partitioned 3 times with 2 volumes
redistilled ethyl acetate
Ethyl acetate fractions combined
and evaporated to dryness
1
Residue dessicated for 15 min.
i




Fig.6. The Extraction of Progesterone from Plasma
Sample
1
20-200jjl(x2) diluted pi asma + half volume absolute alcohol
Whirl 4- mix
Add 2.0ml redistilled petroleum spirit
Vortex mix 10 min
. /Freeze plasma in dry-ice/acetone mixture
Decant petroleum spirit
Repeat
Pool petroleum spirit extracts
\jr
Evaporate petroleum spirit at 60°C under air stream.
v
Add 1,0ml diluent I to each tube.
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After centrifugation, the supernatent plasma was removed and stored
at -20cC.
For extraction, plasma was diluted ten times with distilled
water and 20-200pl was taken in duplicate for each sample.
Distilled .water (iOOpl) was added to samples of less than 50pl and
half the volume of redistilled alcohol was added to each sample to
prevent hydrogen bonding of proteins in plasma to the antibody.
Progesterone was extracted by adding 2.0ml redistilled petroleum
spirit (boiling point 40-60°C) and vortex mixing for 10 min. The
plasma was then frozen using a freezing mixture consisting of dry-
ice in acetone and the petroleum spirit was decanted off. This
process was repeated arid the petroleum spirit fractions were pooled
and evaporated to dryness in a stream of air at 60°C. 1.0ml of
diluent I for progesterone RIA was then added to each of the tubes.
The extraction procedure for progesterone from plasma is summarised
in Fig.6.
4. Radio-Immunp-Assays for the Measurement of Prostaglandins and
Progesterone
a. Prostaglandin Fg ,v
Samples were assayed using an antibody raised and tested in
the laboratory (Dighe, Emslie, Henderson, Rutherford and Simon 1975)
using the double antibody method of separating bound from unbound
radioactive prostaglandin. A list of cross reactivities of the
antibody is given in table 1.
One vial was prepared as a background count for radiation
by adding 0.7ml diluent III to 13ml scintillation fluid A. Four
"counting standards" containing 0.65ml diluent HI and 50pl (30pg)
tritiated PGF2 ^ in 13ml scintillation fluid A were prepared. Four
"zero standards" ("0") were then prepared, consisting of 0.6ml
diluent III per assay tube and four "non-specific binding standards"
(NSB), consisting of an excess of "cold" PGF2eJ< (lOng/ml) in 0.65ml
diluent III. A further nine "standards" of PGF2oc were prepared
dissolved in diluent III. Each standard solution of ^^"2 <x was
dispensed out into assay tubes in triplicate (0.5ml per tube). To
each tube was added 50pl (30pg) of tritiated PGF2 ^ (^HPGF2 ^ ,
"tracer") and 50pl antibody (at a dilution of 1:1500 in diluent III)
and the solutions were mixed using a "whirlimix". 30pg tracer was
also added to each "0" standard and each NSB standard. Antibody
( 50,j 1) was also added to the "0" standards. After an incubation
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period of 1 hr at room temperature, normal rabbit serum (RRS - yOpl
of 1:140 dilution in diluent III) and donkey anti-rabbit serum,
(daRS-50^i1 of 1: 15 dilution in diluent III) were added to the nine
standards and also the "0" and NSB standards. The solutions were
then mixed on the "whirlimix".
Following incubation for 16 hr at 4°C, the tubes were
centrifuged at 4°C and 1720 x g for 30 mins (Fisons MSB centrifuge).
The supernatent liquid was then decanted off into vials containing
13ml scintillation fluid A and after shaking, the vials were
counted for 4 min in a liquid scintillation counter. A standard
curve (Fig.7) was plotted of $ binding of the ^HPGF^ ^ against
the amount of non-radioactive "cold" PGF^ ^
The sensitivity of all radio-immuno assays was defined as the
amount of "cold" prostaglandin or progesterone giving a 10$ fall in
binding, measured from the "0" standards. In all assays, the
upper limit of the working range was determined as the sensitivity
of the assay and the lower limit was determined as the concentra¬
tion of "cold" prostaglandin or progesterone at which there was a
2$ decrease in the slope of the curve.
Examples of the standard curves obtained for each assay
are given in Figs. 7, 8, 9 and 10. The dotted curves represent
the limits of the range of curves obtained for all assays.
Standard curves for all assays fell between the upper and lower
dotted curves. The values for the working range and sensitivity
of each assay, in table 4, are the values obtained for the middle
curve in Figs. 7» 8, 9 and 10. The highest value for sensitivity
obtained during the course of the work described in this thesis
for each of the assays were: PGF^ ^ == 80pg, PGE^ = 30pg,
6-oxo-PGF.j. = 60pg and progesterone = 55Pg« The sensitivity value
of all assays were equal to, or lower than these values.
Details of all radio-immuno assays used are given in tables
3 and 4. Samples were assayed in three volumes in duplicate
and the coefficient of variation between duplicates was calculated.
If this value exceeded 15$, samples were re-assayed. Therefore,
the maximum intra-assay coefficient of variation was 15$, however
for most samples the value was less than 10$. The inter-assay
coefficient of variation was calculated from two tubes containing
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in duplicate, a known amount of prostaglandin or progesterone,
which were added to the end of each assay. The between assay (inter-
assay) coefficient 0f variation was calculated from these duplicated
standards.
b. Prostaglandin E^
An antibody PGE^ was purchased from the Pasteur Institute,
Paris, and a list of cross-reactivities is given in table.1. Tri-
tiated PGE^ (^HPGE^ - 10pg in 50pl diluent I) was used at 1:100
ampoule dilution (in 50pl), of antibody. A series of eight
"standards" in duplicate (in 0.5ml diluent I) were prepared and "0"
and MSB standards as for PGF^ RIA. After a 2 hr incubation at
room temperature NRS (50pl of 1:140 dilution in diluent I) and
PARS (50jul of 1: 15 dilution in diluent I) were added to each tube
and the contents were mixed and left for 16 hr at 4°C. The pro¬
cedure was then as for PGF^ ^ RIA, one background and four
"counting standards" for PGE^ having been prepared as for PGF2 ^ .
c. 6-oxo-Prostaglandin F-^
For this assay diluent I was used initially, but was then
replaced by diluent II.
The antibody for this assay was raised in the laboratory and
the tritiated 6-oxo-PGF^^ (^H 6-oxo- PGFloc ) was also made in the
laboratory (Dighe, Jones, Poyser 1978). The cross-reactivities
Fig.7.
Exampleofstandardcurvefor dio-imrouno-assayfpros aglan inF2̂(PGF2 <). NSB=cnSpecificBindingstan ard. "O"=ZerostandardN.S.BanM0"r fertomiddlecurv .Curvesfoallssayfell betweenthupp randlo rd tec rv s.



















for the antibody are given in table 1. Four "0" standard, four
NSB standards and ten standards in triplicate were used. The
antibody was used in a dilution of 1:650 in diluent II and 50pl
3
was added to each tube. 30pg H6-cxc-PGF.j ^ was used in 50pl
diluent II.. Incubation time was 2 hr at room temperature.
DARS (50pl of 1:8 dilution of diluent II) was then added prior to
incubations at 4°C for 16 hr.' The procedure was then as for
PGF2 ^ RIA .
d• Preparation of Samples for Assay of Prostaglandins by RIA
Samples to be assayed for prostaglandins were extracted
into ethyl acetate (see 1. previously). Three volumes of 20~50Gpl
we're dispensed in duplicate, to check for parallelism between
volumes, and the ethyl acetate was blown off under a stream of air
at 45°C. A volume of 0.5ml of appropriate diluent was added to
each tube prior to RIA. Two "blanks" were added to the end of
each assay consisting of 20-500pl ethyl acetate evaporated to
dryness and 0.5ml diluent added. Two tubes containing a known
quantity of prostaglandins in 0.5ml diluent were also added to
check the interassay coefficient of variation.
e* Radio-Immuno-Assay for Progesterone
Progesterone, extracted with petroleum spirit (see 3.
previously) from peripheral plasma samples, was measured by an
RIA developed by Dighe and Hunter (1974) and described by Peyser
and Horton (1975). The cross reactivities are given in table 2.
The dilution of antibody was 1:2000 in diluent I (50pl/tube) and
30pg H Progesterone (in 50pl diluent l). Incubation time was
2 hr at room temperature. NRS (50pl of 1:140 dilution in diluent l)
and DARS (50pl of 1:15 dilution in diluent i) were used. Ten
triplicate "standards" in a volume of 1.0ml diluent I were used and
four "0" and four NSB standards were prepared. The procedure was
as for RIA for prostaglandins but with the addition of a further
1.0ml dil uent I to each tube prior to centrifugation. The super-
natent liquid was decanted into vials containing 10ml scintillation
fluid B and the vials were shaken for 3 min before counting for
4 min on a liquid scintillation counter.























E2 0.8$ 100$ 6.8??
E, 0.65$ 15.1$ 2.0$
A2 0.04/? 0.14$ 0.036$
b2 0.145/? 0.05$ 0.031$
f2« 100?? 0.17$ 5.8$
F2p 0.833/? - -
15-oxc-F0 2.8$ m»
I5-0X0-E2 - 0.58$ -
100*/? - 0.12$








Ll_1OX01sO 1.2$ 0.002$ 100$
*Crcss reactivity for the PGF^ ^ Antibody with PGF^ is 100$,
however, the rat uterus contains only trace amounts of PGF,
I
(Fenwick, Jones, Naylor, Peyser, Wilson 1977) and so interference
with the measurement of PGFis negligible and the same applies
for the'cross reactivity of PGE^ with the PGE2 antibody.
Cross reactivities were determined by using the method of Dighe
et al (1975).
Fig.10.










Table 2. Cross Reactivities of Progesterone Antibody used for
Radio-Immuno-Assay.




lip hydroxy progesterone \2%
11-oxo-progesterone \$%,








5<*.pregnane 3|3,20<x ,diol 0.003%












*As determined by Dighe and Hunter(l974).


















































5. Purification of Tritiated Prostaglandin Fg by Column Chromatography
3
The column used for purification of tritiated 2oc^ ^^2 <*■ ^
for RIA, was packed with Lipidex 1000 (31cm x 3cm) and a straight
phase solvent system was used to elute the prostaglandins (Brash and
Jones 1974).. The column was washed and left to equilibrate over¬
night in the following solvent mixture: hexane (lOO): dichloroethane
(lOO): ethanol (l5): glacial acetic acid (0.1%). Before using the
column, ten drops were taken for liquid scintillation counting to
determine the level of "background" radioact'wity(this was acceptable
at 5/'° of the fraction containing the highest number of counts).
The radioactive PGF2c< was taken to dryness in a pear-shaped
flask by rotary evaporation at 40°C. The residue was redissolved
in 0.5ml of the solvent mixture and loaded onto the top of the column
using a Pasteur pipette. The flask was then rinsed three times with
0.5ml of solvent mixture and each rinse was loaded onto the column.
The columm was then run at a flow rate of lOml/hr and thirty fractions,
each of 3.0ml, were collected. A sample of 0.02ml of each fraction
was taken and added to a vial containing 5ml of scintillation fluid I
and the vials were counted on the scintillation counter for 1 min. A
graph of fraction number against number of counts was then plotted
(Fig.ll). From the graph, the fractions containing HPGF2^ were
determined i.e in this case fraction 16-19. These fractions were
pooled and the test tubes were rinsed with methanol which was added
to the flask. The pooled fractions were taken to dryness in a
rotary evaporator at 40°C and the residue was redissolved in 7.0ml
methanol. Three 0.02ml aliquots were taken and added to vials
containing 5ml scintillation fluid which were counted using an
external standard chemical ratios count for 4 min so the DPM could
be calculated. From this value, the amount of radioactivity
recovered from the column was determined and more methanol was
added to give a final concentration of 5pCi/ml.
Radio-labelled PGE2 was purified in a similar manner, but
using a solvent mixture of: hexane (100): dichloroethane (lOO):
ethanol (l0): glacial acetic acid (0.1^). The ^HPGE2 was found to
run in fractions 18-21 in this system.
ir
Fig.11.
Purification of radioactive prostaglandin Fg^ for
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6. Derivitisation and Assay of Prostaglandins by Gas Chromatography-
Mass Spectrometry using Multiple Ion Detection.
a - Instrument Details.
The gas chromatograph — mass spectrometer used was a 7070F dual
focusing model from VG Micromass Ltd. The gas chromatograph column
was 3% 0V1 on a diatomaceous skeleton, 100-120 mesh. Helium carrier
gas pressure was 15psi. The multiple ion detection (MID) traces were
recorded on a six channel Rikadenki (Mitsui Electronics U.K. Ltd.)
pen recorder.
b. Assays for Prostaglandin D2 and Thromboxane Bp
i. Derivitisaticn
A series of five "standards" of PGO2 and TXE^ in methanol were
prepared i.e 0, 75, 150, 300 and 600ng/tube and the methyl ester of
each was formed by adding 1.0ml diazomethane solution (9 parts diethyl
ether: 1 part methanol) and allowing to react for 5 min at room
temperature. The solution was then removed under a stream of
nitrogen at 45°C. 300ng of the ethyl ester of PGO2 and 300ng of the
ethyl ester of TXB2 were then added to each tube and the solvent was
again removed under a stream of nitrogen at 45°C. The standards were
then dessicated under vacuum for 5 min. The n-butyl oximes were
formed by adding 3 drops of O-butylhydroxyhydroxylamine hydrochloride
(5rng/ml in pyridine) to each tube. The tubes were left overnight at
room temperature and heated for 30 min at 60°C the following morning,
or alternatively, were heated at 60°C for 3 hr on the same day.
Pyridine was then removed under an air jet at 60°C and the standards
were placed in a dessicator under vacuum for 15 min. Finally, the
trimethyl-silyl ether derivative was formed by adding 25pl bis (tri-
methylsilyl) -trifluoroacetamide (BSTFA) to each tube and heating
at 60°C for 20 min. Standards were injected into the gas chroma¬
tograph - mass spectrometer (GC-MS) in volumes of 8pl, each"standard"
oF PGO2 and TXB2, therefore containing 100ng of the ethyl esters of
PGD2 and TXB2 respectively, as internal standards.
ii. Construction of Standard Curves for PG0o and TXB2
The retention times for the standards on the GC-MS column were
recorded . Their carbon values were then determined from a plot of
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retention time against the carbon number, of a series of fatty acids
injected at the same column temperature. The ion at m/e 420 (+M-90,-7l)
of the methyl ester, butyl oxime, trimethylsilyl ether derivative of
PGD2 (Me.BuO.TMS), carbon value 25.7 was monitored continuously by
multiple ion detection (MID). The corresponding ion at m/e 434 of
the ethyl ester, butyl oxime, trimethylsilyl ether of ^^2 (Et.BuO.TMS)
carbon value 26.1 was monitored as internal standard. The ion at
m/e 301 of TXB2 (Me.BuO.TMS) carbon value 26.4 was monitored, together
with the same ion produced by the Et.BuO.TMS derivative of TXB2, carbon
value 26.9 which was used as internal standard. (See Figs. 12 and 13
for breakdown of molecules). The height of the peaks produced by
continuously monitoring these ions was measured and the graph of
the ratio of peak heights of standard PGD2 or TXB2, to the peak height
of internal standard, was plotted against the amount of standard PGD2
or TXB2, The standard error of the mean (S.E.M.) for six injections
at the mid point of each graph was less than 5% (Figs. 12 end 13).
c. Assay for 6-oxo-Prostaglandin F^ ^ using the 3,3,4,4-tetradsuterated"Compound as internal Standard " "
A series of "standards" i.e 0, 50, 100, 200, 400 and 800ng/tube
of 6-oxo-PGF^^in methanol, were prepared and 400ng of tetradueterated
6-oxc-PGF^^ was added to each tube as internal standard. The Me.BuO.TMS
derivatives of each "standard" plus deuterated internal standard
were prepared as described previously (6bi). Finally, 20pl BSTFA
was added to each tube and 5pl were used for injection into the GC-MS.
The carbon value for the second isomer of 6-cxo-PGF^ was determined
(26.2). The ion at m/e 491 (+M~2x90) of 6-oxo~PGF1cX Me.BuC.TMS
was monitored and the corresponding ion at m/e 495 of the tetradueterated
compound was monitored as internal standard. A standard curve was
then constructed for 6-cxo-PGF^^ (Fig.14) as previously described
for P(X>2 and TX82«
d. Preparation and Assay of Samples for Gas Chroroatography-
Tlass Spectrometry
A known proportion of each extracted sample (in 10ml ethyl acetate)
was taken and evaporated to dryness in an Eppendcrf tube at 45°C under
a stream of cir and then dessiccited under vacuum for 5 min. Redistilled
me thanol (lOOpl) was added to each tube. Samples to be assayed for
PGD2 and TXB2 were methylated, using diazomethane, as before. The
corresponding ethyl ester (300ng) was added as the internal standard
Fig.12.
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and the n-butyl oxime trimethylsilyl ether derivatives were formed
as described for the "standards". Samples to be assayed for
6-oxo-PGF, were derivitised after the addition of 400ng of the
1 e<
deuterated compound. Samples for PGD^ and TXB„ assay were
dissolved in a final volume of 25^il BSTFA and 8jil was used per
injection into the GC-MS. Samples for 6-oxo-PGF.^ assay were
dissolved in a final volume of 20jil BSTFA and 5pl/injection was used.
A standard curve was constructed for each assay as described
previously (6bii). The peak height of each ion monitored was
measured and the ratio of this, to the peak height of the monitored
ion of the known amount of internal standard, was calculated. By
reading this ratio off from the standard curve which had been con¬
structed, the amount of prostaglandin in the tube could be determined
and hence, the total amount in the original sample could be calculated.
Due to small changes in the sensitivity of the GC-MS from
day to day, standard lines obtained differed slightly between assays.
These small variations are compensated for however, by the construc¬
tion of a new standard line for each assay, using the same range of
standard concentrations and by adding the same amount of internal
standard to each of the "standard" tubes and each of the assay tubes.
The standard error of the mean, calculated from six injections at
the mid-point of each of the standard lines (Figs. 12, 13 and 14 )
was less than 5$ for each assay.
7. Assay for Prostaglandin D^ using a method of Platelet Aggregation
Prostaglandin D^ (PGD^) released from the pregnant rat uterus
in vitro (see section II), was also measured, after solvent extrac¬
tion, by a method of platelet aggregation.
Blood was obtained from human volunteers and collected into
citrated dextrose (lml/^ml blood). The blood was then centrifuged
at 600 x g for 15 min at room temperature using a Multex MSB' centrifuge.
After centrifugation, the supernatent platelet rich plasma (PRP) was
siphoned off.
0.5ml PRP was placed in a cuvette and diluted with 0.45ml of
0.9$ saline. Maximal aggregation was obtained by addition of 0.05ml
adenosine diphosphate (ADP) to give a final concentration in the
cuvette of 5*10 M (Fig.15). Aggregation was measured by the
turbidometric method of Born (1962) using an Upchurch BIO37346
aggregometer coupled to a Vitatron pen recorder.
Fig.15. '^————
Aggregationofplateletsinduc dbyadenosinediphosphate(ADP5x10M)ad ed arrowsndinhibitedby2minpre-incubaticnw hPGD2.=5x10ADP, b=5ngPGD2+x10*6MADP,cn10"6M ,d=2 gPGD2 5x10~6MADP.
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ADP-induced platelet aggregation is inhibited by PGD^ in a
dose-dependent manner (Mills and Macfarlane 1977). A dose-response
-6
curve of the percentage inhibition of aggregation caused by 9x10 M ADP,
againBt the dose of PGD2 added, was set up. PGD2, dissolved in 0.9$
saline, was added to the cuvette in a volume of 0.05ml and incubated
with stirring at 37°C for 2 min prior to addition of ADP (Pig.15).
A known amount of the solvent extracted sample, to be assayed for
PGI>2 was taken and the ethyl acetate removed under an air stream at
45°G. The sample was then diluted with 0.9$ saline and 0.05ml of
each dilution was incubated with the platelets (as for standard PGDg)
until two dilutions were found which corresponded to two doses of
PGD2. (Fig.l6). The total amount of PGI>2 contained in each sample
could then be calculated.
The results obtained by this method are given in Section II,
table 5, and are compared to those obtained by GC-MS. Values
estimated by platelet aggregation are in the same range as those
obtained by GC-MS and there is no significant difference between the
two sets of results (Student's "t" test).
SECTION II
PROSTAGLANDINS, THROMBOXANES AND THE
PREGNANT RAT UTERUS AT TERM
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Introduction
The uterus from a day 22 pregnant rat, when removed and freed
of conceptuses, exhibits spontaneous activity when suspended in an
organ bath filled with Krebs' solution. PGF2^and PGE2 are released
into the bathing fluid and the amounts of released have been
measured (Vane and Williams 1973). The spontaneous contractions of
the uterus and the release of prostaglandins are inhibited by the
addition of prostaglandin synthetase (cyclo-oxygenase) inhibitors such
as indomethacin and meclofenamate, to the organ bath. Contractions
can be restored by the addition of PGE2 and , with PGE2 being
the more potent. Since the output of PGE2 and PGF2C< and the spon¬
taneous contractions in this in vitro system are greater on day 22
(the day of parturition) than on earlier days of pregnancy, a role for
these prostaglandins in parturition in the rat has been suggested.
Hcwever, these studies were performed before thromboxanes and
prostacyclin (PG^) were discovered. Consequently, the following
experiments were performed to measure the release of prostacyclin
and thromboxane, in addition to the classical prostaglandins, from
the pregnant rat uterus at term.
The more accurate methods of radio-immuno-assay (RIA) and gas
chromatography-mass spectrometry (GC-M5) rather than bioassay were
used for analysis. The effect of the cyclo-oxygenase inhibitor,
indomethacin and the prostacyclin synthetase inhibitors, 15-hydro-
peroxy arachidonic acid (.15-00HAA) and tranylcypromine, on contrac¬
tions and prostaglandin release has also been examined.
Methods
1. The Release of Prostaglandins from the day 22 Pregnant Rat Uterus
in vitro " ~~ "
Mature female Wister rats were caged with a light cycle of 12 hr
day and 12 hr night, light changes occurring at 08,00 hr and 20.00 hr.
They received food and water ad libitum. Vaginal smears were taken
daily and examined microscopically. Day 1 of the oestrous cycle was
taken as the day of maximum cornification, preceding the day of
leucccytic infiltration. All rats used exhibited regular 4 day
cycles. The female rats were mated singly by placing them with male
rats of proven fertility on the afternecn of day 4 of the oestrous
cycle. Mating was assumed to have taken place during the dark period
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between day 4 and day 1. This latter day became day 1 of the
pregnancy and was confirmed by the appearance of spermatozoa in the
vaginal smear.
Three rats were allowed to go to term and were found to deliver
during the dark period between day 22 and day 23. Twelve rats for
experimental purposes were used on the morning of day 22 of pregnancy.
The animal was killed by cervical dislocation and the uterus quickly
removed and placed in Kreb's solution. The uterus was divided into
two horns which were cut longitudinally and freed of foetuses and
placentae. Each horn was dried, weighed and suspended in 80ml organ
bath containing Kreb's solution at 37°C bubbled with a mixture of
oxygen (95%) and carbon dioxide (5$). A tension of 2g was applied to
each uterine horn. Isotonic contractions were recorded using a Vitatron
pen recorder for four consecutive periods of 15 min. After each
15 min period, the bath fluid surrounding each uterine horn was
removed and collected and the bath refilled. The four fractions
from each horn were pooled and the prostaglandins extracted (see
Basic Methods Section I). The amounts of prostaglandins in the
extract were then measured either by RIA (PGE^, PGF^^ and
6-oxo-PGF^^ ) or by GC-MS (PGD^j TXBg) and PGD2 was also measured
by the platelet aggregation method (see Basic Methods Section i).
The presence of PGE^ and PGFg ^ were confirmed by GC-MS by monitoring
the ions at m/t 295 and 423 respectively at the carbon values
obtained for standards of PGE^ (25.9) and PGF2C< (23.9).
In one experiment, the effect of indomethacin on the release
of PGF2 and PGE2 was investigated. Fluid from a 15 min control
period was collected and then fluid from 2 x 15 min periods in the
presence of 0.6 and 1.2jig/ml indomethacin, respectively. Each sample
was solvent extracted and prostaglandins measured by RIA.
In three experiments the release of prostaglandins from the
term pregnant uterus (PGE2, and 6-oxo-PGF1 ^measured by RIA),
over four consecutive 15 min periods was determined, in order to
ascertain whether or not the rate of release of prostaglandins altered
over the four periods of time, as this may have affected the interpre¬
tation of results of experiments performed using prostaglandin
synthesis inhibitors.
2. The Effects Of Pro staglandins on the Day 22 Pregnant. Ret Uterus in vitrn
In some experiments, one uterine horn was kept as a control,
while indomethacin (5-10pg/ml) was added to the bath containing the
second uterine horn to render it quiescent (Vane and Williams 1973).
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The effects of prostaglandins added to the bathing fluid of
the quiescent horn were then recorded. Prostaglandins were
dissolved 0.9$ saline at pH 7.5 and added to the bath fluid in
volumes up to 1.0ml. Each dose of prostaglandin was tested two or
three times on a minimum of three preparations.
5. The Effects of 15-hvdroperoxv Arachidonic Acid and Tranylcypromine
on the Day 22 Pregnant Rat Uterus in vitro
a. Preparation of 15-hydroperoxy Arachidonic Acid (15-OOHAA)
The product is prepared by the action of the soya bean
lipoxygenase enzyme on arachidonic acid:-
The generation of a conjugated diene system allows the reaction to
be followed by UV light absorption at 254nm, and similary the
product can be quantified.
The compound is a rather unstable hydroperoxy acid which can
be reduced to the hydroxy compound with stannous chloride in water.
A solution (0.5mg/ml) of soya bean lipoxygenase was prepared
in 0.1M triphosphate buffer (Tris) pH 8.0 and 0.5ml of the enzyme
solution was added to 150ml Tris buffer containing 5-10mg arachi¬
donic acid. The mixture was stirred at room temperature for 15 min
until the reaction was completed (monitored by UV light at 254 nm),
The pH was reduced to 4.0 with /lO hydrochloric acid (HCl) and the
reaction mixture was shaken twice with an equal volume of ether. The
ether extracts were pooled. The ether was then washed with 0.2 x the
volume of water, the ether was then separated and dried with the minimum
quantity of anhydrous sodium sulphate, which was removed by filtration.
The ether was evaporated at room temperature on a rotary evaporator.
COOH
Arachidonic Acid 15-00H Arachidonic Acid
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and the residue was rea'issolved in 1.0ml hexane for further puri¬
fication by high pressure liquid chromatography (HPLC). The
separation of 15-00HAA from any unconverted arachidcnic acid and any
of the hydroxy compound which may have formed was thus achieved.
The solvent system used for HPLC was hexane and isopropanol
in the ratio of 10:1 with 0.1% glacial acetic acid added. The column
was packed with Partisil PAC arid the HPLC was performed on an 848
Pump Model from Du Pont Instruments. The column flow rate was
2ml/min. A maximum of 50pl of the extract was injected onto the
column each time. The compounds were detected by UV absorption at
234nm (Fig 17a). The firs t peak to appear was the hydroxy compound
(3y min) followed by the hydroperoxy 2 min later. The seccnd peak
was collected and quantified by UV absorption. (The extinction
coefficient E for a 1M solution of 15-00HAA is 25000)
1M = 334g/l = 334mg/ml = 25000
therefore 334pg/ml = 25
whereoc = Extinction value obtained
therefore oc x 334 = Concentration being
25 measured pg/ml
The 15-C0HAA was stored in methanol at-20°C before use. It
was found to remain stable under these conditions for at least 2
weeks.
In order to verify that the product collected was authentic,
a known volume was removed after HPLC separation and shaken with a
saturated solution of stannous chloride in water for 5-10 min. The
hexane fraction was then separated and subjected to HPLC to observe
the change in retention time from that of the hydroperoxy to that of
the hydroxy compound (Figs. 17a and 17b). The 15-0HAA was then
collected and derivitised for GC-MS.
b. Derivitisatipn of 15-CH Arachidcnic Acid for GC-MS
The methyl ester, trimethylsilyl ether derivative of 15-0HAA
was formed, as previously described for prostaglandins and the
derivative was then subjected to GC-MS using a 3% 0VI column. The
Me.TMS derivative cf 15-0HAA was found to have a carbon value of 21.4.
The structural analysis is shewn in Fig.18, dong with the mass
spectra obtained. The mass ion (M+) is at m/e 406 and the major
(base) peak was found at m/e 225 resulting from cleavage of the
omega chain. Peaks were also obtained at m/el73 (M-233) and
m/e 335 (M~7l). Other fragmentations are due to loss of TMS0H (M-90)
Fig.17aondb»
Arrowsindicatei jectionpoints. Fig.17a(bottomfpage).Separationof(a)15-hydroxyarachidonicaci(15-OHAA from(b)15-hydroperoxyarachidonicac(15-00HAAbhigpressureliquid chromatography(HPLC)anddetecti nbyUVlightabsorp ionwavelength234nm. Fig.17b(topofpage).HPLCracbt inedaf erreduc ioof15-00HAAt 15-OHAA,(peak)7withstannouschlor de.
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at Ve'and (M-90-71) at m/e 245.
Thus, the compound obtained from the action of soya bean
lipoxygenase on arachidcnic acid was shown t.o be 15-0CHAA by:
reduction to the hydroxy compound with stannous chloride, shewn by
a change in retention time to that of the hydroxy using HPLC and
detected by UV absorption. The structure of the substance thereby
obtained was proved to be that of 15-CHAA by GC-MS.
c. The Effects of 15-Hydroperoxy Arcchidcnic Acid and Tranlcypromine
on the Day 22 Pregnant Rat Uterus in vitro
The bath fluid from a 15 min control period of contractions,
was collected and the bath refilled. 15-0CHAA dissolved in 0.2 - 0.6ml
polyethylene glycol (PEG) or tranylcypromine dissolved in 0.9% saline
pH 7.5, was then added to the bath and the effects recorded over a
15 min period. The bath fluid surrounding the uterus was collected
for extraction of prostaglandins at the end of this 15 min period.
Three doses of 15-00HAA were used, 25, 30 and 40pg/ml. Tranylcypromine
was used at 500 jjg/ml. It was found that up to 0.6ml PEG could be
added to the bath without any effect on the tissue. Saline alone, also
did not effect the tissue.The number of uterine horns used was 3 or 4 per group;
d. The Removal of 15-Hydroperoxy Arachidcnic Acid from Extracted
Samples
The samples of extracted bath fluid were to be assayed for
prostaglandins using RIA. It was therefore necessary to establish
the cross-reactivity of 15-00HAA with the antibodies used for RIA, as
any of this compound which was extracted along with the prostaglandins,
may have interfered with the assays.
The cross reactivity of 15-OOHAA with the PGF2 ^ and PGE2
antibodies was found to be very low at 10% drop from the "0" standard
(0.09% and 0.005% respectively). However, at the concentrations
used for experiments, it may still have interfered with the RIA. It
was therefore thought necessary to remove the 15-0CHAA from the solvent-
extracted samples, by column chromatography, before performing the RIA.
It is not necessary to remove the 15-00HAA before GC-MS as the
compounds are separated on the GC column. Tranylcypromine does not
cross react with the RIA antibodies.
A silicic acid column was used to separate the 15-C0HA<\ from
prostaglandins. The following three solvent fractions were used
for elution.
61
Fraction Toluene Ethyl Acetate Methanol Total Volume(ml)
FI 80 20 - 150
FII 50 48 2.0 150
Fill 50 48 2.0 50
4g of silicic acid were weighed out and allowed to soak in a small
volume of FI. The column was then packed and left to equilibrate
overnight in FI.
In order to determine if the 15-00HAA could be removed in FI,
lpCi of arachidonic acid was added to the incubation mixture for
the preparation of 15-0CHAA (see this Section, 3a). After separation
and quantitation the 15-0CHAA ("cold" plus radio labelled) was dissolved
in 1.0ml FI and loaded onto the column using a Pasteur pipette. The;
flask was washed three times with 0.5ml FI which was also loaded onto
the column. The column was then run under gravity at a flow rate of
1 drop/second and the three fractions were collected. After column
elution, three lOOpl aliquots of each fraction were added to vials
containing 10ml scintillation fluid (PCS cocktail/toluene-" 2/l) and
counted for 10 min on a liquid scintillation counter. The results
are given below:-






Therefore, 81% of 15-CCHAA recovered from the column was found in FI.
e. To Determine the Elution of Prostaglandins by Fractions used in the
Separation of 15-00HAA from Extracted Samples
The column was again allowed to equilibrate overnight in FI.
The following morning, 0.5ml of FI containing 0.66 uCi of tritium
3
labelled ( H) PGE2 and lOug "cold" PGE2, was loaded onto the column.
The column was run as previously described and the three fractions
were collected. Each fraction was evaporated to dryness using a
rotary evaporator at 40°C and the residue was redissolved in 1ml
methanol and 100pl of each fraction added to vials containing 10ml
PCS/tol uene scintillation fluid. Three counting standards containing
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0.026pCi of HPGE2 in 20pl methanol were set up and the vials were
counted using an external standards chemical ratios channel for 4 min.






















3922.07 32.43272 37972.1 2.2572
4050.14 32.60472
FII 86413.1 32.33472
102198 31.90472 983400 5872
106409 32.44672
Fill 2515.18 32.20572
2683.51 32.31872 23951.7 272
3487.45 24.72472
Therefore, 53/2 of radio-labelled PGE2 was recovered in FII and 2% in Fill.
It was assumed that 2% methanol was sufficient to elute all prostaglandins
from the column. In all experiments, FII and Fill were pooled before
measurement of prostaglandins.
In order to determine the recovery of prostaglandins from the
columns, samples of extracted bath fluid from the day 22 pregnant uteri
were assayed for prostaglandins before and after chromatography.
Prostaglandins E2, anc' 6-oxo-F.j^ were measured by RIA and PGD2
and TXB2 were measured by GC-MS. Results for these recoveries are
given below:-














The lew recoveries obtained from PGF2et ,6-cxc-PGF.j^ and TXB2 suggest
that not all of the prostaglandins were eluted by the solvent mixtures
from the columns. A more polar mixture may have improved recoveries.
In experiments to investigate the effects of 15-CGHAA and tranylcypro¬
mine, all control and treated samples were subjected to column
chromatography. The results have not been corrected for recoveries
since I was chiefly concerned with comparing the amounts of prosta¬
glandins and TXB2 produced by treated compared with untreated uterine
horns and not with absolute amounts released, as these latter para¬
meters have already been measured. Obviously, an estimate of the gross
amounts can be obtained by multiplying the uncorrected value by the
mean recovery. It was not possible to calculate the recoveries of
all prostaglandins by using internal radioactive compounds, since only
tritiated and radioactive carbon labelled prostaglandins were available,
which is an insufficient number to correct for all the prostaglandins
and thromboxane.
Prostaglandins in extracted samples were measured by RIA
(PCF2cx , PCE2, 6-cxo-PGF1 ^ ) or by GC-MS (PGDg). TXB2 was also
detected by GC-MS but was below the limits of sensitivity of the
assay.
In three experiments, the effects of 15-COHAA on the release of
6-cxo-PGF, as measured by GC-MS, was investigated. These were per¬
formed to compare the results with those obtained when the 6-cxo-PGF.j,.,
was measured by RIA. Bath fluid was collected from one control uterine
horn and one treated with 30jjg/ml 15-CCHAA, after a 30 min period.
Bath fluid samples were then extracted and release of P0I2 from the
centrcl and treated herns was compared, the prostaglandins being
measured as its metabolite 6-cxo-PGF^ , by GC-MS.
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Results
1. The Release of Prostaglandins from the Term Preqnant Rat Uterus
in vitro*
The amounts of prostaglandins and thromboxane released from
the day 22 pregnant rat uterus are shown in Fig.19. Prostaglandin D2
was found to be released in the greatest quantities with a mean value
(+ standard error) of 655-141ng/g/hr. Thromboxane B0 (313-35ng/g/hr)
and the PGI2 metabolite, 6-oxo-PGF-| ^ (229i28ng/g/hr) were also
released in large quantities and PGF2 ^ (l29i59ng/g/hr) and PGE2
(30-llng/g/hr) were released in smaller amounts. An example of the
trace obtained after subjecting the bath fluid sample to GC-MS using
MID, is given in Fig.20.
The value quoted above for PGO2 is from results obtained by
GC-MS. Some samples were assayed for PGD2 by the method platelet
aggregation as described in Section I, in addition to GC-MS assay.
The two sets of results are given in the following table :-









Mean - S.E.M. 655-141 677-18 7
Therewas no significant difference between the values obtained by
either assay method.
2. The Effects of Prostaglandins and Thromboxane on the Day 22
Pregnant "Rat Uterus in vitro""
The spontaneous contractions of the uterus were inhibited by
adding 5-10jjg/ml indcmethacin to the bathing fluid. Contractions
could be restored by addition of prostaglandins to the organ bath.
Prostaglandin E2 was the most potent spasmogen, restoring contractions
at 2ng/mj. PGF2 ^ was effective at 8ng/ml and PGI9 at 24ng/ml. It
was found that the uterus could be sensitised by addition of 8ng/ml
Fig.19.
The release of prostaglandins and thromboxane from the
day 22 pregnant rat uterus in vitro. ^^2' anc*
6-oxo-PGF^ ^ , were measured by radio-immuno-assay.
PG0o and TXB0 were measured by gas chromatography-
mass spectrometry. Number of animals = 12. s.e.w.
Prostaglandins( /g/hr)
Fig,20.
Multiple ion detection trace of a sample of
extracted bath fluid from the day 22 pregnant
rat uterus in vitro, showing (a) ,
carbon value 23,9 monitored by the ion at
m/e 423, (b) PGD2 carbon value of the second
isomer 25.7 monitored by the ion at m/e 420
and 418 (c), (d) TXB2 carbon value 26.4 monitored
by the ion at m/e 301, the methyl ester trimethyl-
silyl ether, butyl oxime of each prostaglandin was
used. Peak (e) is the ethyl ester, trimethylsilyl
ether, butyl oxime of TXB2 used as internal standard




PGI2 to the bath fluid and would then contract on addition of a
further l6ng/ml. Contractions could not be obtained by adding 8 or
l6ng/ml of PGI2 as a sin£le ^ose (Fig.2l).
PGD2 was also found to be spasmogenic, but a larger dose
(60-120ng/ml) was required. The PGI2 metabolite, 6-oxo-PGF1 ^ and
TXA2 metabolite, TXB2 were found to cause contractions at a dose of
500 ng/ml (Fig.22).
Contractions obtained with PGI2 and PGD2 were qualitatively
different from thossobtained by PGE2 or PGF2^. The contractions
caused by PGI2 and PGI>2 were regular and showed little change in basal
tone of the tissues, (see Figs.21. 22). Contractions caused by PGE2 or
PGFg^ were more frequent and there was an increase in basal tone of
the tissues (Fig.21).
5. The Effects of 15-00H Arachidonic Acid and Tranycypromine on the
Day 22 Pregnant Rat Uterus in vitro
When the 15-00HAA was added to the bath, it was found to
produce a spasm of the tissue and a large increase in tone was observed
(Fig.25). This effect was produced by all three doses of the
compound i.e. 25, 30 and 40pg/ml. When the vehicle (0.2-0<6ml poly¬
ethylene glycol) alone was added to the bath, this effect was not seen.
A similar effect to that obtained with 15-00HAA was seen with 500pg/ml
tranylcypromine, (Fig.23). The spasmogenic effects of these two
compounds was observed both in the absence and presence of indomethacin
(5 - lOpg/ml).
4. The Effect of 15-00H Arachidonic Acid and Tranylcypromine on the
Day 22 Pregnant Rat Uterus in vitro
The results for the effects of the "PGI2 synthesis inhibitors"
on prostaglandin release from the term pregnant rat uterus are given
in Fig.24. The results are expressed as the range of values obtained,
n = 3 or 4 per group. 15-00HAA increased the release of PGE~, PGF0
PGDg and also 6-oxo-PGFIo< . The most dramatic increase was seen in
the release of PGD2 in the presence of the highest concentration of
15-OOHAA, where release increased from the control value of 22- 6 up
to 116- 41 nglg/min. Thromboxane B2 was detected in these samples
(by GC-MS), but the levels were below the sensitivity of the assay
for reliable measurement.
Fig.21.










The effects of PCX^, 6-oxo-PGF.. and TXE^ on the day
22 pregnant rat uterus in vitro, in the presence of
lOpg/ml indomethacin (i).
Figure to be read from right to left. Top trace first,
then bottom trace.
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Theeffectof15-hydroperoxyarachidonic(15-COHAA)antranylcypromin ontheday22pregnantr tut rusinvitro. Figuretobereadfromightleft.T pt acefirst,henbotttrac
70 -
Effects of 15-00H-Arachidonic Acid and Tranylcypromine on the
Day 22 Pregnant Rat Uterus, in vitro.
500pg/ml
Fig. 24. The effects of 15-hydroperoxy arachidonic acid
(15-00HAA) and tranylcypromine on prostaglandin
release from the day 22 pregnant rat uterus
in vitro. Figure shows range of values
obtained n=4/control group and n=3/treated group.
PGE0, PGF0 . and 6-oxo-PGFT , , „ T2' 2 «*• I«measured by R.I.A


























(However, levels did seem te increase in the presence of 15-CCHAA).
The release cf prostaglandins from the uterus was net affected
by tranylcypromine (500pg/ml) except fcr which showed a significant
fall (pzlO.Ol) f rem the control value.
The results obtained by RIA, for the release of PG^, reflected
by the levels of its metabolite 6-cxo-PGF.j^ , were unexpected. The
experiment was therefore repeated en uteri obtained from three rats and
the 6-cxo-PGF.j ^was measured by GC-MS. These experiments have been
described previously (see Methods, this section) and the results are
given below in table 6. An example cf the trace obtained for the
measurement of 6-oxo-PGF^ ^ by GC-MS is given in Fig.25.
Table 6 .













In two experiments the release from the treated horn was not
significantly different to control. In the third experiment however,
there was a large increase in the amount of 6-cxo-PGF^^ obtained
from bath fluid surrounding the treated horn.
5. Release of Prostaglandins from the Day 22 Pregnant Rat Uterus
in vitro, over Four Consecutive Periods of Fifteen HinutesT
The increase in prostaglandins release from the uterus in the
presence of 15-CCHAA was not due merely to an increased release from
untreated tissue over consecutive periods of 15 min. This is illustrat¬
ed by the following table 7.
The release of PGE0, PGF0 and 6-cxo-PGF. is the same cr shows
z Z ot
a slight decrease from cne collection period to the next. There are no
large increases in prostaglandin release as was observed in the presence
of 15-COHAA.
Multiple ion detection trace of the assay for
6-oxo-PGF.j ^ in the extracted bath fluid from the
day 22 pregnant rat uterus in vitro, monitored by
the ion at m/e 491, using the tetradeuterated
compound as internal standard, monitored by the




£ Release of Prostaglandins from the Term Pregnant Rat Uterus in vitro
over Four Consecutive Fifteen Minute Periods.
p rostaglandin
Release, 4 x 15 min Periods ng/g/min(n=3)
1' 2 3 4
pGF2~ 3.1 2.7 1.9 1.9
pge2 1.2 1.0 1.2 0.9
6-oxo-PGF.j ^ 3.5 3.1 2.1 2.0
6. The Effect of Indcmethocin on Prostaglandin Release from the Day 22
Pregnant feat Uterus, in vitro
One experiment was performed to investigate the effect of
addition of indomethacin to the bath fluid, on prostaglandin release
(see Methods this section). Indomethacin treatment was found to
reduce the release of PGE2 and PGf^^ G dose dependent manner, as
shown in the table 8 below:-
Triklo P Effect of Indomethacin on Prostaglandin Release from the Term Pregnant RatCUXG
-Uterus in vitro (n = l).
Prostaglandin












These experiments have shown that prostaglandins and thromboxane
are released from the rat uterus on day 22 of pregnancy in vitro. The
amounts of PGF2 released, measured by RIA were found to be in the same
order, but slightly lower, than those reported by Vane and Williams (1973)
who used bioassay. PGE2 was released in smaller amounts than PGF2 ^ .
Since these initial studies of Vane and Williams, prostacyclin (Fenwick
et al 1977) and thromboxane (Williams and Downing 1977), have been shown
to be produced by the rat uterus. Results obtained in this section
have shown the release of large amounts of ^^2 anc* ^^2 (measurec' as
their more stable metabolites, 6-oxo-PGF-| ^ and TXE^, respectively) from
the day 22 pregnant uterus, in vitro, in quantities greater than PGF?
and PGE2. Williams, Dembinska, Kiec, Zmuda and Gryglewski (1978) have
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shewn that myometrial and decidual cell fractions from the day 22
pregnant ret uterus, synthesise PG^* as estimated by inhibition
cf platelet aggregation. In addition, they claimed that the rat
placenta, at this time, does net produce PG^, due to the presence
of a placental prostaglandin synthetase inhibitor (Williams,
Harrowing and Downing 1979) which produced an inhibition cf PG^
synthesis by uterine microsomes. Zamecnik and Kennedy (1979)
however, found that the placental tissue from pregnant rats dees
produce PGI2 when measured as 6-cxo-PGF^^ by GC-MS. Alsc there is
an increase in the tissue level on day 20 compared to day 15, with
further increases occurring on day 21, day 22 and during labour on
day 23. Zamecnik and Kennedy (1979) also report increasing levels
of TXB2 in decidual and placental tissue and amniotic fluid from
day 15 to day 23 of pregnuncy in rats, which is in keeping with the
findings of Downing and Williams (1977). In consequence therefore,
it seems that any measurement of PGI2 prcduction and its inhibition,
from tissue incubates or microsomes, by platelet aggregation methods,
as used by Williams et al (1978), shculd be treated with caution
owing to the possible antagonism cf the actions of PGI2 by TXA2
produced simultaneously.
As has been stated previously, 6-cxo-PGF^ a< and TXE^ were
found to be released from the term pregnant rat uterus in vitro, in
amounts greater than PGF2o< and PGE2. However, the prostaglandin
found to be released in by far the largest quantities was PGD2(Fig.19).
Katori, Harada, Yamashita, Ishibushi and Miyazaki (1978) have also
reported PGD2 to be a major product released frcm the pregnant rat
uterus, although no measurements were made. In 1973 Vane and Williams
reported the appearance of a spot cf unknown identity following thin
layer chromatrcgraphy (TLC) of an extract of fluid which had bathed a
term pregnant rat uterus. The position of the spot on the TLC plate
however, was not that which might hove been expected for PGD2, in
the solvent system used. It may have been due to 6-cxo-PGFj ^. The
question arises as to a physiological role for prostaglandins and
thromboxanes in parturition in the rat. In the present study, the
spasmogenic potencies of PGE2 and PGF2 o< were similar to those reported
by Vane and Williams (1973), with PGE2 being mere potent than PGF2 ^ •
PGI2 was found to be spasmogenic,
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but was less potent than PGF^ . 6-oxo-PGF^ , produced contractions
only at a very high dose level (500 ng/ml) and lower doses were
ineffective in producing contractions. The effects of PGl£ o" the
isolated, human uterus have been reported as stimulating an increase
in tone and. frequency of contractions (Whilhelmsson, Lindblom,
Hamberger, Samsoie, Hammarstrom, Wiquist and Samuelsson 1979). PGI2
has also been reported to relax the human uterus (Omini, Pasagaklian,
Folco, Fano and Berti 1978; Omini, Pasagaklian, Burnetti, Falco and
Berti 1979), although PGI2 was found only to contract the pregnant
rat uterus in the present studies. The type of contractions
obtained on the pregnant rat uterus were visibly different from those
obtained with PGE2 or PGF• Those obtained with PGIj were more
regular, but less frequent, with no change in basal tone of the tissue,
while PGE2 and PGFg produced frequent, irregular contractions and
an increase in tissue tone (see Fig.2l). The contractions produced
by PGI2, appear, in my opinion, to be much more related to the synch¬
ronous, regular but intermittent type of contraction necessary for
expulsion of the foetus during parturition than contractions produced
by PGE2 or ^^2'* .Mitchell, Ellwcod, Anderson and Turnbull (1978) have
reported a marked increase in the levels of 6-oxo-PGF^ ^ in the maternal
utero-ovarian vein, foetal plasma and amniotic fluid of sheep during
active labour. 6-cxo-PGF. has also been found in maternal plasma
I
and amniotic fluid of the Rhesus monkey in late pregnancy (Robinson,
Natale, Clover and Mitchell 1979) and uterine tissues (particularly
decidua and placenta) taken from the late pregnant Rhesus monkey
produce PGIq in vitro (Mitchell, Hicks,Thorburn and Robinson 1979).
It may be that the proposal of Fuchs et al (1976) discussed in the
introduction is true i.e. that the role of PGF2 ^produced by the
endometrium (Williams, Harney and Sneddon 1974) at term, is only to
cause luteolysis and a fall in plasma progesterone ievels and that
the myometrium synthesises another prostaglandin/PGI2 (Williams et
al 1978)/which contributes to the uterine contractions of parturition.
Williams, El-Tahir arid Marcin-Kiewicz (1979) report a synergistic
spasmogenic acticn cf PGl^ with oxytocin (and also of PGI2 with PGF2C< )
when the two compounds are added together to the fluid surrounding
the term pregnant rat uterus, in doses which are subthreshold for
production of contractions when added singly. This synergism between
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between these compounds may also contribute to foetal expulsion.
PGI2 has been found to be capable of releasing renin from
the kidney (Wharton, Lazar, Smigel and Oates 1979). Renin is
the enzyme necessary for the formation of the vasoactive peptide,
angiotensin II. Angiotensin II also has a potent spasmogenic
effect on the uterus (Dubin and Ghodgoankar 1979)» and the uterus
of various species is known to contain renin (Gross, Schaetelin,
Zeigler and Berger, 1964; Ferris, Gordon and Mulrow 1967? Hodari,
Carretero and Hodgekinson 1969? Skinner, Lumbers and Symonds 1968),
although to my knowledge the rat has not been investigated. When PGI2
was added to the bath fluid, there was a short delay before contrac¬
tions were seen (Fig.2l). It could be that PGI2 releases renin which
causes the formation of angiotensin II, which then causes the uterine
contractions. This would explain the delay observed after the addition
of PGI2 to the bath. This suggestion is purely speculative since it
does depend upon the tissue containing precursor of angiotensin II.
However, it would be interesting to test the hypothesis by using an
angiotensin antagonist such as saralasin, or an angiotensin converting
enzyme inhibitor e.g. Squib 19225.
Besides stimulating the uterus to contract, PGI2 is also a
potent vasodilator (Moncada,Gryglewski, Bunting and Vane (1976a).
Its production by the uterus may be to increase the blood supply
through the uterus and placenta during pregnancy. However, the
effect of PGI2 on blood flow through pregnant uterus and maternal
and foetal placenta is not known. Terragno, Terragno, Pacho, Iczyk
and McGiff (1974) have reported that uterine blood flow in the pregnant
dog is reduced by indomethacin, and this effect can be reversed by
infusion of arachidonic acid. However, it could not be reversed by
PGE2 infusion. Hence it is possible that PGI2 and not PGE2 was
mediating the increase in uterine blood flow in this case.
It has been recently suggested that PGI2 is involved in
cervical ripening (Ellwood, Mitchell, Anderson and Turnbull 1979).
There is a significant increase in production of PGE2 and 6-oxo-
PGF^ o< by the sheep cervix in vitro at delivery compared to late
pregnancy. The cervical venous effluent also shows a dramatic
increase in PGE2 and 6-oxo-PGF^ ^ levels during the 12 hr preceding
delivery. It has been suggested that PGE2 and pgi2 act syner_
gistically to soften cervical connective tissue in the sheep.
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Thromboxane E^, measured as described in Section II,
presumably reflects the release of its unstable precursor TXA2
(Hamberg, Svensson and Samuelsson 1975; Svensson 1978) from the
uterus. TXB,j levels have been found to rise in the placenta, decidua
and amniotic fluid of the rat during late pregnancy (Zamecnik and
Kennedy 1979). Decidual microsomes from the day 22 pregnant rat
have been shown to produce TX82 (Downing and Williams 1977). ^^2
is known to constrict a number of blood vessels e.g. rabbit aorta
(Hamberg, Svensson, Wakabayaski and Samuelsson 1975), swine
coronary artery (Svensson and Hamberg 1976) and human umbilical
artery (Tu remo, Strandberg, Hamberg and Samuelsson 1976). Its
release from the uterus may be therefore, in order to constrict
placental blood vessels and reduce blood loss after birth.
Recently TXA2 (l50ng/ml) has been found to increase the tone and
frequency of contraction of strips of human uterus (Whilhelmsson,
Lindblohm, Hamberg, Sansoie, Hammarstrom, Wiquist and Samuelsson
1979) and it is possible that TXA^ may also contribute to expulsion
of the foetus at term. ^^2 was ^oun<^ b® a weaker spasmogen
on the rat uterus in the present study, though it is possible that
it could contribute to the increased contractions of the uterus
at term. However, although TXB2 has been found in the amniotic
fluid and maternal plasma of sheep and human during parturition
(Mitchell, Kierse, Anderson and Turnbull 1978; Mitchell, Hicks,
and Robinson 1979), no distinct trends could be found and a role
for thromboxane in parturition in these species was therefore not
apparent. Mitchell, Hicks, Thorburn and Robertson (1978) on the
other hand, have found a small increase in TXB^ in the amniotic
fluid of the Rhesus monkey at term, compared to late pregnancy,
but the authors suggest that other prostaglandins rather than
thromboxanes are involved in the initiation of parturition.
The finding that PGf^ was prostaglandin released in
the largest amounts from the isolated, term pregnant uterus, was
unexpected and raised the question as to why this particular path-
way of arachidonic acid metabolism is so active in this situation.
PG02 was found to have a spasmogenic effect on the isolated,
pregnant uterus, but the potencyuas much less than that of other
prostaglandins released (PGE2 and PGI2^* It has been
suggested, that in some instances, PGT^ may produce its effect
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by acting at PGF£^ receptors (Norton and Jones 1974). This action
would explain its high equipotent molar ratio, due to lower affinity
and/or efficacy when compared to ' ^CS8^bly, ac**n9
via this mechanism to contract the rat uterus, which would explain
its lower potency. On the other hand, Jones (1978) has reported
that the rat may possess a PK)*> sensitive vasoconstrictor system.
Therefore, it is possible that PCC^ released from the uterus brings
about a vasoconstriction of placental blood vessels just after
parturition and possibly acting in this way along with TXA£.
A prostaglandin-endoperoxide isomerase, which gives a high
yield of PGD, has been isolated from the rat spleen (Van Dorp,
Buytenhoek, Christ-Hazlehof, Nugteren and Van Der Ouderaa 1978;
Christ-Hazlehof and Nugteren 1978) and a similar enzyme has been
found in rat brain tissue (Yamamoto 1979). Rat lung, stomach and
intestine also give a high conversion of endoperoxide (PQ^) to PGD
(Van Dorp et al 1978)and it seems likely in view of this and of
results reported here, that the rat uterus also contains such a
system. The PGI^ to PGD2 isomerase in the rat spleen is a soluble,
cytoplasmic enzyme. This is in contrast to enzymes which convert
PGH2 into PGE2, PGF2 c< , PGI2 and TXB2, as these are membrane-bound
(Og ino, Miyamoto, Yamamoto and Hayaishi 1977; Needleman, Moncadar,
Bunting, Vane, Hamberg and Samuelsson 1976; Johnston, Morton, Kinner,
Gorman, McQuine, Sun, Whittaker, Bunting, Salmon^Moncada and Vane
1976). Fatty acid cyclo-oxygenase, which converts arachidonic
acid to PG endoperoxide is also membrane bound. Since the two
enzymes needed for the conversion of arachidonic acid into PGD2
via the reaction: arcchidonic acid—» PG endoperoxide —»PGD0, differ
in sub-cellular localisation, Christ-Hazlehcf and Nugteren (1978)
have suggested that any PG endoperoxide which escapes conversion
into the other prostaglandin or thromboxane in the membranes, is
converted by the PGH2 tc PGD2 iscmerase within the cytoplasm. This
transformation protects the tissue from the possible harmful effects
due to overproduction of the more potent prostaglandins and thrombox¬
anes, The much lower potency of PGD2 and its abundant release from
the term pregnant rat uterus, compared to other prostaglandins may
be explained by this theory.
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Hence, one or more physiological roles can be attributed
to each of the prostaglandins and thromboxane released from the
term pregnant rat uterus. Although the studies presented in this
thesis have been performed on the isolated rat uterus only, a
function in vivo is implied by their actions:
1. A luteclytic action for PGF2 .... , followed possibly by a contribu¬
tion in uterine contractions.
2. An increase in blood flow through the uterine and placental
vessels for PGE^, and PGI2.
3. a spasmogenic effect of PGIp on the myometrium resulting in the
synchronous, regular type of contractions associated with parturition,
4. A spasmogenic action of other prostaglandins cannot be ruled out
(pge2, txa2, pgd2).
5. A potentiating effect of pgi« on oxytocin-induced contractions.
(Williams et al 1979).
6. a vasodilatory effect of PGI9 is possibly overcome after parturi¬
tion by a vasoconstrictor effect of TXA2 and PGD2, the release ofwhich may take over the release of PGI2 during the latter stages
of parturition.
7. An action of ^^2 ant* ^^2 *nc'uce cervical ripening at term.
8. The main function of the PGH2 to PGD2 pathway may be one of
"mopping up" of excess precursor.
Further experimentation is needed to see whether the ratio of
the prostaglandins and thromboxane released in vitro is reflected
in vivo, or which prostaglandin(s) is released preferentially.
To further test the possible role of ^^2 *n caus^n9 contrac¬
tions of the rat uterus at term, the reported PGI2 synthesis inhibitors
15-hydroperoxy arachidonic (15-C0HAA) acid and tranylcypromine were
used. However, both compounds were found to produce spasm cf the
day 22 pregnant rat uterus when added to the bath fluid. Consequently,
these drugs were of little use for investigating the significance of
PGI2 in the production of uterine contractions. 15-00HAA and tranyl¬
cypromine produced contractions of the uterus both in the presence
and absence of indomethacin. Furthermore, in the absence of indcmetha-
cin, 15-00HA.A caused a dose related increase in prostaglandin from the
uterus which was surprising and unexpected. This is especially true
for 6-cxo-PGF^ , since 15-0CHAA has been reported to specifically
inhibit P0l2 synthesis from PGH2 by aortic microsomes (Mcncada,
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Gryglewski, Bunting and Vane 1976$.
The high values for prostaglandin production obtained by RIA
were not due to high cross-reactivity of 15-OCHAA with the antisera
used, because the high values were obtained after removal of the
15-OCHAA by column chromatography. Another possibility, was
that the 15-00HAA may have"fed into" the prostaglandin pathways
producing prcstaglandin-like compounds which may then have inter¬
fered with the RIA. However, PGD2 and 6-oxo-PGF^ were measured
by the much more sensitive method of GC-MS, so it is thought
unlikely that such interference could explain the increased release
of these unless any compounds so formed had identical retention times
and produced the same ions as the prostaglandins being measured. In
addition, the corresponding compound, 15-hydroperoxy-8,11,13-eicosa-
trienoic acid does not "feed into the "1 series" prostaglandin
pathway (Hambera and Samuelsson 1967) so it is unlikely that 15-OCHAA
would be converted into prostaglandins of the "2-series". It would
appear, therefore, that 15-00HAA does stimulate prostaglandin produc¬
tion by the pregnant rat uterus in some way. However, it was possible
that the increases in prostaglandin release observed were due to a
non-linear release of prostaglandins from the uterus between con¬
secutive period of time, since prostaglandin release from the uterus
in the presence of 15-00HAA over a 15 min period, was compared with
prostaglandin release over the preceding 15 min, when 15-00HAA was
absent from the bath fluid. However, this possibility was found
not to be the case (see table 7). Prostaglandin release showed no
increase between 4 consecutive 15 min periods of collection in the
absence of 15-00HAA. In fact, some decreases were seen over the 4
periods tested.
It has been reported that 15-COHAA will inhibit the lipoxy¬
genase pathway of arachidonic acid metabolism (see Fig.4 in General
Introduction), in the same concentration as it inhibits PG^ synthase
(Burka and Flower 1979). Lipoxygenase is a soluble enzyme found in
the supernatent liquid fraction after ultra centrifugaticn of a
smashed cell preparation (Nuqteren 1975), whereas the PG endoperoxide
PGI2 converting enzyme is membrane bound (3oWasWovv et al 1976).
The 15-00HAA may, therefore, have easier access to the lipoxygenase
enzyme, when it is added to the bath fluid surrounding the whole
uterine tissue. If this is the case, the resultant inhibition of the
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lipoxygenase pathway may cause more substrate to be available for
the prostaglandin pathways, thus producing an increased release
of prostaglandins. 12-hydroxy-5,8,10,14-eicosatetranoic acid (HETE)
the product of the lipoxygenase pathway has been found to be produced
by the sheep uterus (Jones and Wilson: unpublished results) and the
rat uterus may contain this lipoxygenase pathway. In addition,
Hamberg and Samuelsson (1974) have demonstrated that inhibition of
the cyclo-oxygenase pathway in human platelets with aspirin and
indomethecin gives rise to an increase in the products of the
lipoxygenase pathway suggesting that blockade of one pathway
potentiates the other. Thus it is possible that the increase in
prostaglandin release in the presence of 15-00HAA is not the result
of direct stimulation, but rather indicrectly, as a consequence of
blockinq the lipoxygenase pathway.
Tranylcypromine is, supposedly, another specific inhibitor of
PGI2 synthesis (Gryqiewski, Bunting, Mencada, Flower and Vane 1976)
but treatment of the isolated uterus with the recommended dose for
1007° inhibition in blood vessels (500|jq/ml) did not produce any
reduction in PG^ release. However, a fall in PGEj release was
observed. Rajtar and de-Gaetano (1979) have reported that in the
rat, tranylcypromine is not selective for PG^ inhibition, as they
found that it can also inhibit production of TXA2 in veins and
arteries.
In the case of the isolated uterus, theremav have been a
problem of access of both inhibitors of PG^ production to the
sub-cellular site of action. This was not the case with indcmethacin,
since treatment with this drug caused a dose-related decrease in
release of PGE2 and PGF2 «=< (see table 8) from the uterus, as expected.
From the results obtained in these experiments it appears that
15-0CHAA and tranylcypromine are not selective inhibitors of PGI2
synthesis in the term pregnant rat uterus. The role of PGI2
in the-production of spontaneous activity in the uterus merits
further investigation.
In conclusion, this experimental section has shown the order
of release of prostaglandins in the isolated spontaneously contracting
rat uterus on day 22 of pregnancy is PGD2 TXA2^> PG^^ ^^2^ PGE2
83
This order is the reverse of their spasmogenic potency on the
uterus i.e. PGE2 PG^^- PGD2. Possible roles for
these prostaglandins have been suggested, but their release in vivo
needs examining. It is known that PGE2 and ^^2^ are released
into the uterine venous blood of the rat at term, but other
prostaglandins and thromboxane have not been identified or measured.
SECTION III
THE INVOLVEMENT OF PROSTAGLANDINS IN
IMPLANTATION IN THE RAT
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introduction
The rat uterus has been shown to synthesise prostaglandins
in vitro, during pseudcpregnancy (Fenwick et ol 1977). PGE and PGF
measured by RIA, showed a peak on day 5; the amounts of PGF were
higher than PGE on each day studied. The major prostaglandin
produced was found to be 6-oxo-PGF^ ^ , which was detected by GC-MS,
but not measured due to a lack in the availability of standard
6~oxo~PGF.j at that time. Tamoxifen administered on day 2 of pseudo-
pregnancy, inhibited the increase in prostaglandin production on day 5.
Tamoxifen administered to pregnant rats on day 2, prevents implantation.
(Harper and Walpole 1967). These results suggest that prostaglandins
may be involved in implantation in the rat. It was decided, there¬
fore, that the amounts of PGE2, PGF2 and o-oxo-PGF. produced by
the uterus during early pregnancy should be investigated and compared
with the amounts produced during pseudopregnancy, using RIA and also
using GC-MS for 6-oxo-PGF^ ^ measurements.
One of the first indications of the implantation process is
an increase in vascular permeability at the implantation site. This
can be detected by intravenous injection of Evans or Pontamine, blue
dye, followed by examination of the uterus 1 hr later, for dye re¬
action sites. The time of appearance of these sites in our rats
was determined and the effects of indomethacin on this time of
appearance was investigated. The effects of the indomethacin treat¬
ment on the subsequent development of pregnancy, up to day 9, has also
been investigated.
Methods
1. Prostaglandin Synthesis by the Early Pseudopregngnt and Pregnant
KTrTTJterus" -in vitro
a. Early Pseudopregnancy
Mature female rats undergoing regular four day oestrous cycles,
were caged individually with a vasectomised male on the afternoon of
day 4 of the oestrous cycle and were removed at mid-day on the
following day. Mating was assumed to have taken place during the dark
period between day 4 and day 1 of the cestrous cycle, this latter day
becoming day 1 of pseudopregnoncy. Pseudopregnancy was confirmed
by the lack of subsequent oestrus and/or by the determination of
peripheral plasma progesterone levels. Three rats were allowed to
continue their pseudopregnancy and vaginal smears were taken every
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morning to determine the length of pseudcpregnancy. This was found
to be thirteen days i.e. before the next oestrous cycle.
Rats (4 per day) were taken on the mornings of days 4 to 6 of
pseudopregnancy and cardiac punctures were performed in order to
collect blood to use for determination of peripheral plasma proges¬
terone levels. The rats were killed by cervical dislocation and the
uterus quickly removed, freed of fat, dried and weighed. The
uterus was then homogenised in 15 ml Krebs1 solution (pH 7.5) using
a Fiscrfs glass homogeniser. The homogenate was transferred to a
conical flask and the homogeniser was washed with 5ml Krebs'
solution which was then added to the flask. Homogenates were incu¬
bated at 37°C for 1 hr in a shaking water bath, during which time
they were bubbled with 95% oxygen and 5% carbon dioxide. After
1 hr, the pH of the incubate was reduced to 4.0 with IN HC1 and the
incubate was shaken three times with two volumes of redistilled
ethyl acetate, to extract the prostaglandins. The ethyl acetate
extracts were pooled and evaporated to dryness at 45°C on a rotary
evaporator and the residue was dessicated under vacuum for 5 min.
Dry residues were redissolved in 10ml redistilled ethyl acetate and
stored at -20°C before assay.
Blood taken from each rat, into heparinised tubes (10 i.u./ml)
was spun at 600 x g for 5 min using a bench centrifuge and the
supernatent plasma was removed and stored at -20°C before proges¬
terone was extracted and measured by RIA.
b. Early Pregnancy
Mature female rats exhibiting regular 4 day oestrous cycles
were mated individually with males cf proven fertility on the after¬
noon of day 4 of the oestrous cycle. Mating was assumed to have
taken place during the dark period between day 4 and day 1. The
rats were removed from the male cages at mid-day on day 1 and this
became day 1 of pregnancy.
Rats (5 per day) were taken on the mornings of days 3 to 7 of
pregnancy and a blood sample was taken by cardiac puncture from
each rat for determination of peripheral plasma progesterone levels.
The rats were killed by cervical dislocation, the uterus was removed
and subjected to exactly the same procedures as the uteri from
pseudopregnant rats.
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Samples from both early pseudopregnancy and pregnancy were
assayed for PGF2 x , PGE2 and 6-oxo-PGF^ by RIA. 6-cxo-PGF^
was also measured by GC-MS.
2. Measurement of Basal Uterine Tissue Levels of Prostaglandins
in the Pregnant Rat
The uteri from rats from days 3 to 7 of pregnancy (3 animals
per day) were removed, dried and weighed and immediately placed in
15ml absolute alcohol and homogenised. The glass hcmogeniser was
washed with 5ml absolute alcohol which was then added to the hcmo-
genate. The alcoholic homogenate was then diluted with water, the
pH reduced to 4.0 with IN HC1 and shaken with three times two
volume redistilled ethyl acetate and the ethyl acetate extracts
were pooled and evaporated to dryness as previously described. The
residue was redissolved in 10ml redistilled ethyl acetate and stored
at -20°C before RIA for PGF2 PGE2 and 6-oxo-PGF^
3. Studies on the Metabolism of Prostaglandin F2 by the Early
Pregnant Rat Uterus in vitro
Uteri from rats from days 3 to 7 of pregnancy (3 animals per
day) were taken, divided into the right and left horns and the two
horns were weighed. One horn (a) was homogenised in 8ml Krebs'
3
solution containing 0.25pCi HPGf^ • The homogeniser was washed
with 2.0ml Krebs' solution which was added to the homogenate. The
second horn (b) was homogenised in 8.0ml Krebs' solution containing
0.25pCi ^HPGF2 , 20pg (2pg/ml) "cold" PGF2 v and 2.0mM nicctineawviAt
adenine dinucleotide (llAD+). Horn (a) was to determine metabolism
of PGF2^during the incubation procedure described in (l) with
endogenous co-factors and horn (b) was to determine the maximum
metabolic capacity of the tissue by using saturating levels of
precursor i.e. non-radioactive "cold" PGF2 t< and the co-factoryNAD*.
Each homogenate was bubbled with 95% oxygen and 5% carbon dioxide
and incubated for 1 hr at 37°C in a shaking water bath. After 1 hr.
the pH -was reduced to 4.0 with IN HC1 and the homogenates subjected
to solvent extraction as described in (l).
The dried residue of each extract was taken up in 0.5ml
methanol and spotted onto silica gel thin layer chromatography plates
at a distance of 3cm from the end of the plate. The plates were then
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run first in the FV1 solvent system (Anderson 1969) to a distance
from the origin of the spot to lorn from the top of the plate and then
in the GCM solvent system (Millar 1974). The plates were then dried
and scanned under a Panax radioactive plate scanner to determine the
position of any radioactive peaks.
Three silica gel plates were spotted with 10pg standard PGF2,
I5-0X0-PGF2 rK ,13,14,dihydro-15-oxo-PGF2 ^ respectively and were run
in theFVl and GCM solvent systems. The plates were then dried and
sprayed with phosphomolybdic acid in methanol and heated in an oven
at 115°C for 10 min in oi'der to visualize the spots. The Rf values
of PGF2<V and the two metabolites for these solvent systems were
then calculated and compared to those obtained for each metabolsm
study. The Rf value of the standards are given belowi-
PGF2 ^ = 0.35
15-oxo~PGF2 = 0.54
13,14,dihydro-15-oxo-
PGF2 ^ - 0.59
The Rf values for the peaks detected by the radioactive
scanner were determined. It was found that the two peaks of
prostaglandin metabolites did not separate completely and so the
plates were divided into two zones only/for scraping i.e the zone
corresponding to the PGF2 ^ peak and the zone corresponding to the
metabolites. Each scraping was washed twice with 5.0ml methanol to
elute the prostaglandins and the methanol washings were pooled and
taken to dryness on a rotary evaporator at 45°C. The dry residues
were redissolved in 0.6ml methanol of which 0.5ml was added to vials
containing 10ml scintillation fluid A (see Basic Methods Section) and
the vials were counted for 4 min on a liquid scintillation counter.
4. The Effects of Indomethacin Treatment on Early Pregnancy in the
"Rat"
a. Effects oh Implantation
Pregnant rats were token on the evening of day 5 of pregnancy
in order to determine the time of the appearance of the "uterine dye
reaction site" indicative of the start of the implantation process.
Rats were anaesthetised with 7ml/lcg 25% urethane solution given
intraperitoneally (i.p.). The jugular vein was cannulated and 0.5ml
of a 0.5% solution of "Evans blue" dye was injected. One hr later
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bleed samples for progesterone measurement were taken by cardiac
puncture (Evans blue dye did not cross react with the progesterone
antibody). The rats were killed and the uterus examined for dye
reaction sites. The first appearance of the dye reaction sites
in the rats used for these experiments was 02.00 hr on day 6 of
pregnancy (6 animals).
One group of rats was treated with indomethacin, in order to
investigate the effects of inhibition of prostaglandin synthesis
on implantation. Indomethacin was given sub-cutaneously in a dose
of 3mg/Kg, di ssolved in 0.7ml of polyethylene glycol on the morning
(09.00) and evening (17.00) of days 3 and 4 of pregnancy. Plasma
half life of indomethacin in the rat is 4 hr and indomethacin is
cleared from the plasma at 24 hr (Hucker, Zacchei, Cox, Bredie,
Cantrell 1966).
Five of the rats treated with indcmethacin were examined at
02.00 hr on day 6 of pregnancy and five at 10.00 hr on day 6 of
pregnancy. Peripheral plasma progesterone levels were measured in
control (vehicle treated) and indomethacin treated rats at 02.00 hr
on day 6 and at 10.00 hr on days 6 to 9 of pregnancy (5 animals/group).
b. Effects on Development of Early Pregnancy
One group of animals (n=ll) treated with indomethacin on days
3 and 4 of pregnancy were killed on day 9 and the uteri removed.
Uterine weight was taken and the appearance and number of implantation
sites per horn was noted. These parameters were compared to those
obtained in control animals (n=12) examined on day 9 of pregnancy.
Results
1. Uterine Prostaglandin Synthesis and Peripheral Plasma Progesterone
levels in "the Early, PseITdopreqnant"~"an5'"Pregnant ITot~7n vitro
a. Early Pseudopregngncy
The amounts of prostaglandins synthesis by homogenates of
pseudopregnant rat uteri, during a 60 min incubation period are shown
in Fig.26. The production of all prostaglandins showed a peak on
day 5 of pseudopregnancy. The amounts of PGE2, PGFg ^cmd 6-oxo-PGF^ ^
formed were significantly higher on day 5 than on day 4 (p <0.05,p4.0,005,
p<0.005 respectively), or day 6 (p-<0.05, p<0.005, p<.0.05
respectively). The ratio of the amounts of 6-oxo-PGF^ ,PGF2i.<PGE2
formed was 4:2:1, for all three days.
Fig,26.
Prostaglandin production by the pseudopregnant rat
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Table 9a Prostaglandin Production by Uterine Homoge+nates from
Pregnant and Pseudopregnant Rats. Mean - S.E.M.
Day Pregnancy ng/100 mg tissue n=5/group Pseudopregnancy ng/lOOmgtissue
n = 4/group
PGE2 , 6-oxo-PGF.,loC pgf2o< pge2 6-oxoPGF.,lex.
4 6oi8 29-4 267^5 28-9 9-3 49-7
5 53-5 57-6 346^46 115-17 40-10 198^25
6 44-6 24-5 230-47 44-3 18-3 124-8
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b. Early Pregnancy
The amounts of prostaglandins synthesised by honiogenates of
pregnant rat uterus during a 60 min incubation period are given in
Fig. 27. The production of ^^2 sk°wec* a peak on day 5 of
pregnancy, as was seen with the pseudopregnant uterus. Production
on day 5 was significantly higher than on day 4 or day 6 (p^- 0.005).
The amounts produced by the pregnant and pseudoprognant uterus were
comparable.
The production of 2 <x Pre9nar,f uterus, did not show
a peak on day 5. This is in contrast to the pseudopregnant uterus
(compare Figs.26and 27). Production of PGF2(Xby the uterus did show
a small but significant increase from day 2 to day 3 of pregnancy
and the levels plateaued between day 3 and day 6 and fell(again
significantly) on day 7. PGF2 production was significantly higher
than PGE^ on days 3 and 4 of pregnancy (p-'-O.OOQS and p^-0.005
respectively) but there were no significant differences on days 2,
5, 6 and 7.
The major product formed by the pregnant rat uterus was
6-oxo-PGF.j ^ as was the case for the pseudopregnant uterus. Levels
of 6-oxo-PGF.j were five or six times higher than those of PGF2^ or
PGE2. The production of 6-oxo-PGF.j ^ was found to increase from
day 2, reach a peak on day 5 and then fall on days 6 and 7.
Production of 6-oxo-PGF.j ^ tended to be higher in the pregnant than
in the pseudopregnant uterus (day 4 p^ 0.0005, day 5 p-^0.01 and
day 6 p-^0.05).
c. A Comparison of the Values obtained for Measurement of 6-cxo-PGF, _
by RIA and GC-M5 1 ^
The amounts of 6-oxo-PGF-j ^ produced by the pseudopregnant and
pregnant rat uterus were measured by GC-MS, in addition to RIA, in
order to compare the two methods. The results are given in table 9,
There was no significant difference between the results obtained by
either method (Student's t test). The trend in prostaglandin
production by the pregnant and pseudopregnant rat uterus from day to




roduction of PGI? by the Pregnant and Pseudopregnant Rat Uterus in vitro. Measured
,s 6-oxo-PGFftx by RIA AND GC-MS. Mean - S.E.M. n= 4 or 5/Group.
ng/lOOmg tissue
Day RIA GC-MS
3 Pregnancy 2.11-41 226-32
4 Pregnancy 267±5 245-10
Pseudopregnancy 49^7 79-17
5 Pregnancy 346-46 309^12
Pseudopregnancy 198^25 260^77
6 Pregnancy 230t47 169-40
Pseudopregnancy 124-8 161-13
d. Peripheral Plasma Progesterone Levels
The results for peripheral plasma progesterone levels in the
rat during pregnancy are given in Fig, 28. Levels increased from
33 ng/ml on day 3 to reach a peak of 94 ng/ml on day 5 and the .levels
then plateoued. These results agree with previously reported
findings (Wiest, Kidwell and Balogh 1968; Pepe arid Rothchild 1974).
The peripheral progesterone levels during pregnancy were not
significantly different£row»those measured over a similar period of
pseudopregnancy (see table 10 ). The levels found in pseudopreg-
nancy also agree with previously reported results (Fenwick et al 1977).
t li in ^erlpheral Plasma Progesterone Levels in Pregnant and Pseudopregnanlloble iU Rats. Mean - S.E.M n = 4/5 Group.





2. Basal Tissue Levels of Prostaalandins During Early Pregnancy
The tissue levels of PGE2, ^^2-* anc' ^-oxo-PGF-j from day 3
to day 7 of pregnancy are given in table 11 below. Tissue levels of
all three prostaglandins are low and therevuas no significant difference












in the levels between any two days. Levels tended to be slightly
lower on day 6 than on the other days, although not significantly.
Table 11 Basal Jterine Tissue Prostaglandin Levels During Early Pregnancy.
....
Mean - S.E.M. n = 3/group.
Day of Pregnancy PG levels ng/lOOmg tissue
E2 F2<* 6-oxo-F, ^
3 l.lio.5 2.2+0.5 1.8+-0.6
4 1.8±0.8 3.0±1.0 3.lll.3
5 1.5-0.4 3.0±0.6 3.3^0.6
6 0.9^0.2 0.9^0.2 1.6-0.4
7 l.oto.i 2.2±0.3 3.6-0.5
3* Metabolism of Prostaglandin FpW by Uterine Homoqenates from
Pregnant Rats in vitro
The results, expressed as % metabolism of ot per uni*
weight of uterine tissue, obtained from rats from day 3 to day 7
of pregnancy, are shown below in table 12.
Table 12 Metabolism of PGF9f7t by Uterine Homogenates from Pregnant Rats
— Mean - S.E.M. n = 3/group. in vitro
Day of Pregnancy % Total Metabolism PGF« /lOOmg Tissue







Metabolism tended to be slightly higher (though not significantly) in
the horn (b) with added co-factor and an excess of substrate, on each
of the days of pregnancy. Metabolism of PGf~2 ^ did show a significant
increase (p^0.05) however, on day 6 and day 7 of pregnancy in the
horn with added co-factor (b).
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4. The Effects of Indcmethocin on Early Pregnancy in the Rat
d. Effects on Implantation
The sites for implantation in the uterus were clearly visible
at 02.00 hr on day 6 of pregnancy, due to the increased permeability
of the blood vessels at these sites and consequently, penetration of
the Evans blue dye.
In animals treated with indomethacin on days 3 and 4 of
pregnancy and examined at 02.00 hr on day 6, there were no blue dye
sites visible. Some animals showed small, dark spots in the uterus
which may have been blood clots. Animals treated with indomethacin
and examined at 10.00 hr on day 6 did show dye sites and the number
was not significantly different from vehicle-treated controls,(table 13).
Table 13.
Effects of Indomethecin on the Appearance of Uterine "Dye Sites" in the Early
Pregnant Rat. Mean - S.E.M.
Group (n=5/group) Mean No."Dye Sites"/Horn
Control
Day 6 02.00 hr
5.6-0.6
T reated
Day 6 02.00 hr
0
Control
Day 6 10.00 hr
5.5-0.4
T reated
Day 6 10.00 hr 5.8 to.4
The peripheral plasma progesterone levels of pregnant rats
treated with indomethacin were significantly lower than controls at
02.00 hr on day 6 and at 10.00 hr of subsequent days of pregnancy
(see Fig. 28).
k* Effects on the Development of Early Pregnancy
The number of implantation sites per horn and the uterine
weight of a vehicle-treated control group of rats and on group treated




Effects of Indomethacin on the Development of Early Pregnancy in the Rat.
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Group










Seven of the animals treated with indomethacin showed no
implantation sites and four showed a significant reduction in the
number of implants per uterine horn compared with control rats
(p-<0.0l). The uterine weight of both groups of indomethacin
treated animals was significantly lower than controls (p^O.Ol).
The implanted blastocysts in the indornethacin treated group of
rats, were visibly smaller than those of controls* Two of the
rats in the indomethacin treated group showed clumping of the
blastocysts at the cervical end of the uterine horns. This is in
contrast to control animals which exhibited even spacing of implants
throughout both uterine horns.
Piscussion
The major product formed by both the early pseudopregnant
and early pregnant rat uterus when homogenised and incubated
in vitro was found to be 6-oxo-PGF^ ^ . The amounts produced by
the pregnant uterus were higher than those produced by the pseudo-
pregnant uterus and showed a peak on day 5 of both pregnancy and
pseudopregnancy. The amounts of PGEr> formed during pregnancy and
pseudopregnancy were comparable and again showed a peak on day 5
in each case. However, PGF2 ^ production did not show a peak in
production on day 5 of pregnancy in contrast to day 5 of pseudo-
pregnancy.
Fenwick et al (1977) have also shown peak production of
PGE2 and PGfr2 ex. by homogenates of rat uterus on day 5 of pseudo*"
pregnancy. However, the levels they report are slightly higher
than those reported here. 6-oxo-PGF^ was also reported to be
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the major product formed but no measurements were made in that
study.
The work of Kennedy (1976) and Evans and Kennedy (1978)
reported an increase in the concentration of PGE2 at the site of
implantations compared with other uterine areas in the rat and
a*A
hamster. Kennedy*(197S) later reported similar results when
measuring tha concentration of 6-oxo-PGF-| ^ in the rat. The
increase in synthesising capacity of PGE2 and 6-cxo-PGF-j^ by
the pregnant rat uterus obtained in this section may correspond
to the increase in levels of PGE2 and 6-oxo-PGFy^ at the sites of
implantation reported by other workers. In the rabbit,
Sharma (.1979) has recently reported that PGE levels in the endo¬
metrium and in the uterine venous plasma, increase during the
preimplantation period, reaching a maximum value on day 6
(implantation in the rabbit occurs between day 6i and 7). He
found a change in the ratio of E to F over the period studied,
this change being more marked at the implantation sites. The
results obtained in the present studies in the rat show a
similar change in the ratio of PGE to PGF production by the
pregnant uterus over the period studied with a peak in PGE2 pro¬
duction on day 5, the day of implantation. The results
obtained in this section and by other workers strongly suggest
a role for PGE2 and PGI2 in implantation. The increased pro¬
duction of prostaglandins appears to be due to an increase in the
synthesising capacity of the tissue for two reasons. Table 11
shows that the basal tissue levels of prostaglandins are very
low, indicating that fresh synthesis of prostaglandins must have
taken place during incubation of the homogenised uterus. The
basal levels of prostaglandins in the pregnant rat uterus showed
no significant variation, in contrast to uterine production from
day to day. The metabolism of PGF2^ by the pregnant rat uterus
was also low (table 12), but did show small increases on day 6 and
7 of pregnancy in the horns with added co-factor. This is in
accordance with the observation that uterine prostaglandin
metabolising capacity increases during pregnancy in. the rat
(Flower 1976). However, the small increase in metabolism of
PGFj ^ on day 7 could not account for the decrease in production
observed on this day, especially as NAD was not added to incubates
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in which prostaglandin production was measured. However,
metabolism of PGF9apnly, hos been studied in these experiments
and it would be appropriate to perform such studies with PGE2 and
6-oxo-PGF^ , , which show larger changes in production than PGF2o<
over the period of early pregnancy in the rat. Unfortunately,
due to lack of time, such experiments were not possible in the
present study.
Changes at the nidation site have been likened to an
inflammatory process (Horan 197l). These include vasodilation
and increased vascular permeability. ^^2 anc* ^^2 are known
vasodilators (Jones 1978; Moncoda, Gryglewski, Bunting and Vane
1976) and recently Kennedy (1979 ) reported that PGE2, when
instilled into the uterine lumen of indomethacin treated rats,
increased vascular permeability at decidual sites. Similar results
were not obtained with suggesting that it may not increase
vascular permeability in the uterus. However, the negative
results may have been due to the inherent instability of PG^,
which may not have had sufficient time to act before being
hydrolysed to 6-oxo-PGF^ ^ .
Treatment with indcmethacin on day 3 and 4 of pregnancy,
delayed the appearance of dye reaction sites, which has normally
occurred by 02.00 hr on day 6. Dye sites were visible however
at 10.00 hr on day 6. Similar results have subsequently been
reported by Kennedy (1977), who injected indcmethacin on day 5
only. These findings further suggest a role for prostaglandins
in implantation. However, other possible actions of indometha¬
cin such as delaying the tubal transport of ova, cannct be
excluded.
The indomethacin treatment also interfered with the sub¬
sequent development of pregnancy. Animals treated on day 3 and
4 and examined on day 9 showed an absence, or a reduction in
number of implanted blastocysts. The implants were visibly
smaller in treated animals, compared with controls on day 9 and
the uterine weight was significantly lower in treated animals.
A reduction in the weight of uterine areas containing implants on
day 8,in indomethacin treated rats was reported by Kennedy (1976).
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Horan (l97l) also observed reductions in uterine weight on day 7
in animals treated with sodium salicylate during early pregnancy.
In the rabbit, treatment with indomethacin or antibodies to PGE2
and PGF2 ^ produces retardation of embryonic growth and resorption
(El-Banna, Sacher and Schilling 1976; Elzayat and Stylos 1974;
Hoffman 1978). It would be of interest to examine the effects
of treatment of rats with antibodies to prostaglandins, on implan¬
tation and pregnancy development. The effects of treatment with
indomethacin in vivo, on the production of prostaglandins by the
rat uterus in vitro during early pregnancy, is another obvious
experiment to carry out. There was a significant reduction in
plasma progesterone levels from days 6 to 9 of pregnancy, in
treated animals compared to controls. This was unexpected, and
probably indicates that progesterone production by the ovary was
inhibited either by a direct effect on the ovary, or indirectly
by a reduction in trophic support. It is not known if the fall
in progesterone occurred as a result of the failure of normal
pregnancy development, or whether in fact the fall in progesterone
leads to foetal resorption. Further investigations into the
mechanism of action of indomethacin would be interesting to carry
out. This result was not shown by Kennedy(1976; 1977) who used
a lower dose of indomethacin and who measured progesterone levels
on day 5 only.
Some animals in the group treated with indomethacin and
examined on day 9 of pregnancy, showed a clumping of implants at
the cervical end of the uterine horn. This was in contrast to
controls which showed an even distribution of implantation sites
throughout both horns. This observation was also made by
Kennedy (1977). It is interesting that indomethacin should
adversely affect the even distribution of implants, in view of the
findings that the concentrations of anc' 6-oxo-PGF-j ^ are
higher at implantation sites compared to non-implantation sites in
the uterus (Kennedy 1977; 1978; Evans and Kennedy 1978). It may
be that a local increase in uterine production of prostaglandins
is responsible for the correct spacing of the blastocyst in the
uterus prior to implantation, though this is only speculation.
The increase in prostaglandin synthesis may be stimulated
by the surge in plasma oestrogen observed early on day 4 of
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pregnancy (Shaikh 197l). However, some workers (Dickman and
Dey 1974; Dey and Dickman 1974) have measured changes in Aw-3p~
hydroxysteroid dehydrogenase and oestradiol-17{3-hydroxysteroid
dehydrogenase activity, which is first detectable in the blastocyst
on day 4, peaks on day 5 and declines on day 6. If these changes
in enzyme activity reflect changes in steroid synthesis, then
oestradiol may be synthesised by the blastocyst. Hence the
stimulus for local uterine prostaglandin production may come from
oestrogen secreted by the blastocyst and taken up at local sites
by the uterus. Alternatively, synthesis of oestrogen by the
blastocyst may stimulate its own prostaglandin synthesis which
could be released and taken up by the endometrium and contribute
to vasodilatation and increased vasular permeability at nidation
sites. Sharma (1979) has reported a rise in oestrogen in the
blastocyst preceding a rise in PGE in the blastocyst on day 6 of
pregnancy in the rabbit. It would be appropriate to measure
prostaglandin production by the rat blastocyst.
The profile of prostaglandin production during pregnancy
compared to that during pseudopregnancy, infers that the presence
of the blastocyst is affecting uterine prostaglandin production.
It is possible that factor (s) from the blastocyst may cause an
inhibition of PGF2 synthesis or a redirection of synthesis from
precursor, into other pathways e.g. 6-exe-PGF.j ^ . Production
of 6-oxc-PGF^ ^ during pregnancy was higher than that during
pseudopregnancy, while PGE^ levels were comparable. Overall
prostaglandin production during pregnancy was greater than that
during pseudopregnancy, and this may be due to stimulation by
factor(s) released from the blastocyst.
No measurement of uterine cyclic AMP levels has been
attempted during this study. It would be interesting, in the
light of evidence presented in the introduction for a role of
cyclic AMP in implantation, to investigate whether there is a
rise in cyclic AMP on day 5 of pregnancy which coincides with
the rise in prostaglandin production. Garg, De Scuza and
Chaudhury (1979) have reported that alloxan (an adenyl cyclase
inhibitor) reduces uterine production of PGE and PGF on day 5
and 6 of pregnancy. Conversely, Vesin, Do-Khac and Harben (1979)
report that PGI2 stimulates a rise in cyclic AMP in the endo-
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metrium and myometrium of oestrogen-treated rats. Other studie
which could be performed would be to investigate the effect of
alloxan on implantation and on uterine 6-oxo-PGF^^ production
around the time of implantation.
In conclusion, the experiments performed in this section
support a role for prostaglandins in implantation in the rat.
Since there is no difference in the number of uterine dye sites
in indomethacin treated rats at 10.00 hr of day 6, but there is
reduced number or absence of implanted blastocysts on day 9,
compared with the control group of animals, it would appear that
prostaglandins may also be involved in the development of the
foetus and placenta after the initial increase in uterine
capillary permeability. However, the fact that prostaglandins
cannot reverse completely the inhibition of implantation caused
by indomethacin suggests that prostaglandins are not the only
local hormones involved in implantation. They probably act
together with other local hormones such as histamine which has




It seems that prostaglandins are involved in both parturition
and implantation in the rat, from evidence of an increase in
release from and/or synthesis by the uterus during each process.
In both cases, more than one prostaglandin is implicated. PGE2
and PGI2 appear to be the main prostaglandins involved in implan¬
tation, while roles are implied for ^^2' ' ^^2' ^®2 anc*
TXA2, in parturition. Prostaglandin synthesis inhibitors have been
found to produce detrimental effects on both processes. Treatment
with aspirin, indomethacin, fendozic acid or naproxen causes
increased gestation length and prolonged parturition (Aiken 1972;
Chester, Dukes, Slater and Walpole 1972; Sykes and Maddox 1972;
Csapo, Csapo, Fay, Henzl and Salau 1973) and injection of
antibody prolongs gestation in the rat (Dunn, Humphries,Judkins,
Kendall and Knight 1973). Injection of PGF20; into pregnant rats
leads to a premature decline in plasma progesterone levels (Strauss,
Sokolski, Caploe, Duffy, Mintz and Stanbough 1975), premature
labour (Chatterjee 1976) and abortion (Deis 1969)* Fuchs, Smitisari
and Chantharaksri (1976) found that indomethacin treatment of
pregnant rats near term causes a delated. decline in progesterone
and increase in 20uhydroxyprogesterone and also tJe\av\€di parturi¬
tion. These effects could be reversed by infusion of PGF2CX .
Indomethacin treatment has been shown to delay implantation in
the rat in the present studies, and also by Kennedy (1977).
Although the evidence strongly suggests a role or roles
for prostaglandins in parturition and implantation, it appears
that in each case, other factors are involved. There is evidence
that oxytocin plays an important role in parturition in the rat.
The uterine contractions of labour are indistinguishable from
those induced by oxytocin and there is a marked increase in uterine
sensitivity to oxytocin during the 12 hr pre-partum (Fuchs 1978).
Oxytocin has not been measured in the plasma of rats during
parturition, but there is a decline in pituitary content of oxytocin
during labour (Fuchs and Saito 197l). In addition, stimulation of the
neurohypophysis will induce delivery (Buer, Lincoln and Swaab
1975). It is possible that oxytocin causes release of prosta¬
glandins during parturition. Oxytocin has been shown to stimulate
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prostaglandin release from the non-pregnant rat uterus in vitro
(Chan 1974), although Ishikawa and Fuchs (1978) could not
demonstrate any stimulation of PGF release under the same
conditions. Pelvic neurectomy before mating abolished labour
completely (Carlson and De Feo 1965). The mechanism of this effect
was thought to be a removal of the afferent pathway which causes
reflex activation of the neurohypophysis and oxytocin release/ in
response to cervical and uterine stretching. Thus parturition
was prevented due to an absence of oxytocin. Louis, Lawrence,
Becker and Borden (1978) have found that pelvic neurectomy
performed on day 8, also prevents the increase in plasma PGF
levels which normally occurs on the day of parturition, although
the rise in plasma 20c< hydroxyprogesterone levels which occurs
prior to parturition is not affected. These results suggest that
the pelvic nerves may be necessary for the second surge of
prostaglandins, seen on the day of parturition, but possibly not
for the first surge which initiates functional luteolysis, and
that the second increase in prostaglandin output from the uterus
occurs as a result of oxytocin release from the pituitary.
As regards other factors being involved in implantation,
the delay in implantation in the mouse, due to indomethacin
treatment can only be partially reversed by replacement therapy
with PGE2 or PGF2^(Lau, Saksena and Chang 1973). Complete
reversal can be achieved however by using a combination of PGF2^
and histamine (Saksena, Lau and Chang 1976). The results
presented in this thesis suggest the involvement of both PGI2
and PGE2 in implantation in the rat. It would be interesting
therefore to investigate the effects of treatment with PGI2
alone and in combination with PGE2 and/or histamine, on the
indomethacin induced delay of implantation in the rat.
There may be important roles for PGE2 and PGI2 in both
parturition and implantation, as vasodilatory substances. ^^2
seems also to be involved in the increase in vessel permeability
seen at implantation sites (Kennedy 1979b). At parturition, the
vasodilatory action of PGI2 is possibly balanced against the
vasoconstrictor effect of TXA2 and possibly P®2* su99est®d
function of PGI2 to maintain placental and uterine blood flow
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before and during parturition, becomes unnecessary after parturi¬
tion. Consequently, in the immediate post-partum period, this
vasodilatory action of PGI2 may be over-ridden by an increased
release of TXA£ and PCS^, in order to reduce blood loss after
birth. The spasmogenic effects of PGJ^ on the pregnant rat
uterus appear to be like those one would associate with the
uterine contractions of parturition. PGI2 may therefore have a
role in initiating and maintaining uterine contractility, though
it is possible that PGE2, PGF2^ and also TXAg also have a con¬
tributory role in the expulsion of the foetus. PGI9 also
potentiates the spasmogenic effect of oxytocin on the uterus
(Williams, El-Tahir and Marcin-Kiewicz 1979) and this action may also
aid in foetal expulsion.
The extensibility of the cervix of the late pegnant rat
can be increased by prior administration of PGE2 or PGFp a to the
animal (Hollingsworth, Isherwood and Gallincie 1979). Ellwood,
Mitchell, Anderson and Turnbull (1979) h ave shown dramatic
increases in the production and release from the cervix of PGE2
and 6-oxo-PGF^ at term compared to late pregnancy in sheep. In
view of the high levels of 6-cxo-PGF.j^ released from the rat uterus
at term and the effects of other prostaglandins in the cervix, a
possible role for PGI2 in cervical ripening is implied in the rat.
The increased prostaglandin synthesis at both parturition
and implantation appears to be under the control of oestrogen as
in each case there is a surge of oestrogen prior to the rise in
prostaglandins. Oestrogen is known to stimulate PGF production
by uterine microsomes from oestrogen-treated, ovariectomised rats,
by an effect on the synthesising enzymes involved ( Ham,Cirillo,
Zanetti and Kuehl 1975; Kuehl, Cirillo, Zanetti, Beveridge and
Ham 1976). The rise in PGF production occurs, to some extent,
at the expense of PGE, although PGE production is not completely
abolished. However, in pseudopregnancy, increases occurred in
the production of PGE,-,, PGF2 ^ and 6-oxo-PGF^ by the uterus,
reaching a peak on day 5. The increase in the production of
any one prostaglandin did not occur at the expense of another.
Since Tamoxifen treatment on day 2 largely prevented the increases
in prostaglandin production seen on day 5 of pseudopregnancy,
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Fenwick et al (1977), suggested that the increase in uterine
prostaglandin production occurred as a result of the surge of
©estradiol in the early hours of day 4. Since the oestradiol
would then have to stimulate synthesis of all prostaglandins,
this hypothesis does not agree with that of Ham et al(l975).
However, the oestrogen surge which occurs early on day 4 of
pregnancy (Shaikh 197l), may be responsible for the rise in
PGE2 and 6-oxo-PGF^ production by the uterus on day 5. The
increase in 6-cxo-PGF^ production by the pregnant uterus was
higher on day 5 of pregnancy than day 5 of pseudopregnancy and
occurred partly at the expense of PGF production. Consequently,
2 C»c
the peak in PGF2^ production seen on day 5 of pseudopregnancy
was absent on day 5 of pregnancy. However, overall prostaglandin
production on day 5 of pregnancy was greater than on day 5 of
pseudopregnancy. It may be that oestrogen from the ovary
stimulates the peak in prostaglandin production seen on day 5 of
pseudopregnancy and pregnancy, though oestrogen and possibly other
factor(s) released from the blastocyst, stimulates a redirection
of synthesis and also a further increase in prostaglandin
production during pregnancy.
It is known that PGE2 will stimulate a rise in cyclic AMP
levels in the rat ovary (Kuehl, Humes, Tarnoff, Cirillo and
Ham 1970) and uterus (Bhalla, Sanborn and Korenman 1972) and more
recently, PGI2 has been shown to stimulate cyclic AMP in uterine
tissues (Vesin, Do-Khac and Harbon 1979). It is also known that
cyclic AMP is involved in the implantation process (see General
Introduction) and hence it may be that there is a directing of
prostaglandin synthesis towards PGE2 and PGI2 by factor(s) re¬
leased from the blastocyst, in order to cause the increase in
cyclic AMP required for implantation. Alternatively, thexemay be
release of prostaglandins from the blastocyst, in addition to those
produced by the uterus, to stimulate a rise in uterine cyclic AMP
levels.
On day 5 of pregnancy, the increase in prostaglandin E2 and
I2 synthesis appears to be stimulated by an oestrogen surge,possibly
together with factors from the blastocyst, against a background of
high progesterone levels. In contrast, prostaglandin release at
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term seems to be stimulated initially by an oestrogen surge on a
falling background of progesterone. Zamecnik and Kennedy (1979)
observed an increase in the levels of 6-cxo-PGF^ ^ and TX82 in the
placenta, decidua and amniotic fluid of rats on day 20 of
pregnancy compared to day 15. Levels continued to increase from
day 20 and reached a maximum at parturition on day 23. Hence, at
some time between day 15 and day 20, the stimulus for the rise in
PGIp, and TXA0 production occurs. There is a surge in plasma
oestrogen levels from day 20 - 21 of pregnancy (Shaikh 1971;
Labhsetwar and Watson 1974) which is superimposed on a rapidly
declining background of plasma progesterone, beginning on day
18 - 19 (Shaikh, Naqvi and Saksena 1977; Labhsetwar and Watson
1974). Co nsequently, this changing hormonal environment may
be the stimulus for the initial increased prostaglandin and
thromboxane synthesis and release from the pregnant uterus at
term in the rat. A possible role for oxytocin in the subsequent
release of prostaglandins from the uterus on the day of parturi¬
tion has been discussed previously.
In conclusion, I should like to suggest that there are
important roles for prostaglandins in parturition and implantation
in the rat and that they have more than one function in each
process. In parturition they are involved in luteolysis, mainten¬
ance of adequate uterine and placental blood flow during pregnancy
and parturition (by vasodilatation) and then reducing blood loss
after birth (by vasoconstriction) and I believe contributing to
foetal expulsion, particularly in the case of PG^. Prostaglandins
seem also to be involved in cervical ripening in the rat. Finally,
earlier in pregnancy prostaglandins appear to be involved in the
timing of implantation, in the even spacing of implants in the
uterus, vasodilatation and increased permeability at the implanta¬
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Heparin - Weddel Pharmaceuticals Ltd.
Indomethacin - Merck, Sharp and Dohme Ltd.
Soyabean Lipoxidase - Sigma.
Tranylcypromine - Smith, Kline and French Ltd.
Silicic Acid - Unisil.
Arachidonic Acid (99% pure) - Sigma.
PCS Scintillation fluid cocktail - Amersham/Searle Corporation.
Tritiated Prostaglandin F and E - Amersham Co. Ltd.
2~ 2
Tritiated Prostaglandin D2 and Thromboxane B2 - New England Nuclear
Laboratories.
Deuterated 6-oxo-prostaglandin F^^ ) Gifts from the Upjohn
Prostaglandins F2 ^ , E2, C>2,6-oxo^ ^ and j Michigan,Ku!s?a!°°'
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6-oxo-prostaglandin Fj ^ - Gift from I.C.I. Ltd.
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All other solvents and reagents used, were from B.D.H. Ltd. (Analar
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Prostaglandins and Implantation in the Rat
Christine A. Phillips and N. L. Poyser
Department of Pharmacology, University of Edinburgh. Edinburgh EH8 9JZ, Scotland
There is evidence to suggest an involvement of prostaglandins (FG) in implan¬
tation and subsequent fetal development in rabbits (1,3), mice (6), and rats
(4). Fenwick et al. (3) reported a significant increase in the uterine production
of PGE and PGF on day 5 of pseudopregnancy in vitro. 6-oxo-PGFia was
reported as the major product formed by the pseudopregnant rat uterus. Prosta¬
glandin production by the pregnant rat uterus around the time of implantation
has not been measured in vitro. Production of 6-oxo-PFGia by the pseudopreg¬
nant rat uterus was also measured. The effect of indomethacin on implantation
and subsequent fetal development has also been investigated.
METHODS AND RESULTS
PGE2 and PGF2„ were measured by radioimmunoassay (RIA) while 6-oxo-
PGFia was measured by gas chromatography-mass spectrometry (GC-MS).
PGE2 production by uterine homogenates was found to increase significantly
on day 5 of pregnancy, the reported day of implantation in the rat. PGF2a
production was found to plateau from day 3 to day 6 of pregnancy. PGF2n
production was significantly higher than PGE2 on all days measured except
day 5 when there was no significant difference. 6-oxo-PGFi„ (reflecting PGI2
production) showed a significant increase on day 5 of both pregnancy and pseudo-
pregnancy. Production was maximum on day 5 of pregnancy and was five times
higher than production of PGE2 or PGF2a. 6-oxo-PGFla was significantly higher
on day 4 of pregnancy compared with pseudopregnancy but was not significantly
different on days 5 and 6.
The increase in vascular permeability at the implantation site can be demon¬
strated by intravenous injection of a 0.5% solution of Evans Blue dye. Pregnant
rats were injected with the dye and the uterus examined for "dye reaction
sites" 1 hr later. Our control rats were found to show the dye reaction by
2:00 a.m. on day 6 of pregnancy. However, pregnant rats treated with indometha¬
cin (3 mgAg at 9.-00 a.m. and 5:00 p.m. 011 days 3 and 4) and examined at
2:00 a.m. on day 6 did not show any dye reaction sites in the uterus. If indometha-
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sites were present, their number not being significantly different from control
rats injected with vehicle, 0.7 ml polyethylene glycol.
The effect of the indomethacin treatment by day 9 of pregnancy was also
investigated. In the treated group of animals, seven did not show any implantation
sites and four showed a significant reduction in the number of implants per
uterine horn compared to controls. There was a significant reduction in the
mean uterine weight in animals treated with indomethacin (with and without
implants) compared to controls. Plasma progesterone levels measured by RIA
were significantly lower from day 6 to day 9 of pregnancy in animals treated
with indomethacin on days 3 and 4, compared with controls. Some of the animals
treated with indomethacin and examined on day 6 and some of those examined
on day 9 showed a clumping of the developing embryos around the cervical
end of the uterine horns. This was in contrast to control animals which showed
an even distribution throughout both horns.
DISCUSSION
The increase in synthesizing capacity of the uterus for PGE2 and 6-oxo-PGFla
on day 5 of pregnancy suggests a role for these PGs in the process of implantation
in the rat. Further evidence for a role for PGs in implantation is the observation
that implantation is delayed by treatment with indomethacin. This drug also
interferes with subsequent development of the blastocyst, again suggesting that
PGs are important during early pregnancy in the rat. The reduction in plasma
progesterone seen from day 6 to day 9 of pregnancy may be due to a disturbance
of the pregnancy due to the action of indomethacin on the developing embryos.
Alternatively, the normal development of the pregnancy may be interrupted
by a fall in plasma progesterone levels, possibly due to an action of indomethacin
on the corpus luteum. The disturbance in distribution of the implants within
the uterus in animals treated with indomethacin may indicate that PGs are
also necessary for even spacing of implants. Kennedy and Zamecnik (5) have
reported that the concentration of 6-oxo-PGFia is elevated at the site of implanta¬
tion compared with adjacent uterine areas in the rat. This observation, together
with our findings that 6-oxo-PGFia is the major PG produced by the uterus
around the time of implantation, supports a role for PGI2 in the implantation
process.
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